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Abstract 
Chronic systemic immunosuppression in pancreatic islet transplantation restricts its clinical 
application. This study aims to explore the potential of cell-mediated immune-modulation as 
an alternative to conventional immunosuppressive regimens; specifically investigating the 
innate immunosuppressive properties of human amniotic epithelial cells (AEC).  
 
Cell constructs composed of human islets and AEC (islet:AEC) were bio-engineered in  
rotational culture. Insulin secretory capacity and immuno-modulatory potential were 
characterised using appropriate in vitro assays.  Fluorescence immunocytochemistry and 
multiplex arrays was used to identify putative mediators of the immunosuppressive 
response in isolated AEC monocultures.   
 
Islets and islet:AEC constructs demonstrated sustained, physiologically-appropriate insulin 
secretion. Resting peripheral blood mononuclear cells (PBMC) were activated on exposure to 
human islets but this response was significantly (p<0.05) attenuated in islet:AEC constructs. 
Phytohaemagglutinin (5g/ml)-induced PBMC proliferation was sustained on contact with 
unmodified islets but abrogated in AEC and islet:AEC constructs.  CD4+ and CD8+ T-cell 
proliferation was responsive to AEC; their in vitro expansion both in response to CD3/CD28 
activation and contact with human islets being suppressed by the presence of AEC. 
 
Transplanted islets may thus benefit from an immune-privilege status conferred on them as 
a consequence of their close proximity to human AEC. Such an approach may diminish the 
requirement for generalised systemic immunosuppression in islet transplantation. 
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CHAPTER 1: INTRODUCTION 
 
CLASSIFICATION, AETIOLOGY, PREVALENCE AND TREATMENT 
OF DIABETES MELLITUS 
 
 
1.1. Introduction/Definition and classification of diabetes mellitus (DM) 
Diabetes mellitus (DM) is defined as a group of metabolic disorders, characterized by chronic 
hyperglycaemia with disruption to carbohydrate, fat and protein metabolism, as a 
consequence of defects in insulin secretion, insulin action, or both (ADA, 2009). The 
syndrome presents with characteristic symptoms including thirst, polyuria, blurred vision 
and unexplained weight loss albeit these are often not severe and hyperglycaemia may go 
undetected for many years. The persistent elevation of plasma glucose, if untreated, 
heightens the risk of micro-vascular complications including nephropathy, neuropathy and 
retinopathy (Worrall, 1994, Reichard, 1994, Kilpatrick et al., 2009) and is generally 
considered to increase the incidence of cardiovascular disease, notably stroke, cardiac 
failure and peripheral vascular disease resulting in amputation (Stratton et al., 2000, 
Huysman and Mathieu, 2009).   
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For the purpose of this thesis, and in its simplest form, DM is classified according to the 
pathogenic process underlying the hyperglycaemia; 
 
 Type 1 diabetes (T1DM) caused by near or complete loss of endogenous insulin 
production due to pancreatic islet beta ()-cell destruction which maybe 
autoimmune or idiopathic  
 e.g. with no evidence of anti-islet autoantibodies (Urakami et al., 2002). 
 
 
 Type 2 diabetes (T2DM) a heterogeneous group of disorders characterized by 
variable degrees of impaired insulin secretion, insulin resistance and loss of 
regulation of peripheral glucose metabolism. 
 
 
 Other specific types of DM resulting from an underlying defect or disease process 
which can be identified as disrupting normal -cell function. Such defects result in a 
range of different abnormalities including maturity-onset diabetes of the young 
(MODY) where a genetic defect of beta-cell function results in hyperglycaemia 
occurring at an early age (usually before 25 years of age). MODY is characterised by 
impaired insulin secretion with little or no aberration of insulin action (Gat-Yablonski 
et al., 2006). Other forms of DM in this category include diseases of the exocrine 
pancreas e.g. fibrocalculous pancreatopathy and endocrinopathies e.g. Cushing’s 
Syndrome. 
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 Gestational DM (GDM) characterized as glucose intolerance occurring or being first 
observed during pregnancy (Ben-Haroush et al., 2004a). The definition applies 
regardless of whether the hyperglycaemia is treated with insulin or if it continues 
post-partum, and does not exclude the possibility of previous undiagnosed 
hyperglycaemia. GDM is most likely the result of increased peripheral insulin 
resistance associated with weight gain, hypertension and hyperlipidaemia. In most 
cases GDM subsides following parturition but women with a history of the condition 
have a 30-60% chance of developing overt T2DM later in life (Ben-Haroush et al., 
2004b). 
 
It should be stated that whilst attempts are made to classify DM theoretically, in practice 
it may prove difficult to assign a patient to a specific group due to overlap of the 
presenting clinical symptoms and an inability to ascertain the underlying pathology. 
 
1.2. Prevalence of DM 
DM is a global disease with a rapidly increasing number of individuals being affected. 
According to the World Health Organisation (WHO), the number of people with diabetes is 
projected to rise from 171 million in 2000 to 366 million in 2030 (Wild et al., 2004, Setacci et 
al., 2009) whilst a more recent and alarming estimate by Shaw et al predicts the prevalence 
at 2030 to be 439 million (Shaw et al., 2009). DM is currently more widespread in developed 
countries but this is set to change with the greatest relative future increases occurring in the 
Middle Eastern Crescent, sub-Saharan Africa and India (Setacci et al., 2009, Wild et al., 
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2004). Thus, diabetes in the adult population of developing countries is projected to increase 
by 70% from 2010 to 2030 compared to 20% over the same period in developed countries 
(Shaw et al., 2009).  Factors underlying the massive increase include population growth, the 
advancing age of the population and urbanization with associated lifestyle changes (Shaw et 
al., 2009, Setacci et al., 2009, Wild et al., 2004).  Together these factors will cause the global 
incidence of DM to rise by 54% between 2010 and 2030, representing an annual growth of 
2.2%: nearly twice the annual growth of the total world adult population (Shaw et al., 2009). 
Generally the incidence is similar in males and females but gender-dependent (male-
dominant) differences may occur following puberty and again in the elderly (higher in 
females aged above 70) (Setacci et al., 2009). 
 
 
Table. 1 Prevalence of diabetes – most recent figures comparing England with the 
United States of America 
 
 England* USA** 
 
Adults 2,634,263 25.6 million 
Children 26,400 215000 
 
 
*Figures from the Quality and Outcomes Framework 2010 
** Figures from the American Diabetes Association (ADA) 2011 (see http://www.diabetes.org/diabetes-basics/diabetes-
statistics/) 
 
1.2.1. UK Prevalence of DM 
Estimates for 2011 as provided by the Quality of Outcomes Framework suggest that 4.6% of 
the UK population have some form of diabetes, with over 2.9 million individuals affected. 
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Despite these disturbingly high figures, it should be noted that many cases, particularly Type 
2 DM, remain undiagnosed, suggesting that the overall UK incidence may be greater still. 
 
1.3. Aetiology and Pathology of DM 
1.3.1. Type 1 DM 
The underlying pathology in Type 1 DM (T1DM) is a profound loss of beta cell mass, a 
concomitant cessation of insulin secretion and the onset of chronic metabolic aberration, 
the most prominent feature being hyperglycaemia (Gerich, 1986). The underlying aetiology 
in most instances is the autoimmune destruction of  -cells residing in the pancreatic Islet of 
Langerhans (Nerup and Lernmark, 1981). The process is determined by both genetic and 
environmental factors. With regard to the genetic component of the disease the most 
important genes are located at the major histocompatibility complex (MHC) HLA class II 
region on chromosome 6p21, (once referred to as IDDM1). This region accounts for 
approximately 45% of the genetic susceptibility to T1DM (Buzzetti et al., 1998). The function 
of the genes in this region is well characterised (viz. presentation of antigenic peptides to T-
lymphocytes) yet their involvement in the aetiology of T1DM is not completely understood. 
Higher risk of the disease is associated with HLA-DR3 and HLA-DR4 with additional 
susceptibility linked to the DQ-chains and DQ -chains. In addition to genes which increase 
susceptibility to T1DM, other MHC (major histocompatibility complex) halotypes are 
associated with protection from it.   
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T1DM is characterised as a heterogeneous and polygenic disorder and approximately 20 
non-HLA loci considered to be involved in its pathology have been identified, yet our 
understanding of the function of most of these is limited. IDDM2 on chromosome 11p5.5 is 
considered to contribute 10% towards disease susceptibility (Bennett and Todd, 1996), 
mapping to a variable number of tandem mini-satellite repeats (VNTR). Short class VNTR are 
associated with a higher incidence of T1DM whilst the long class II alleles provide a 
protective effect. Additionally, IDDM12 located on 2q33 is involved in the actions of 
cytotoxic T-lymphocyte associated protein-4 (CTLA-4) which is involved in modulation of the 
immune response (Nistico et al., 1996) and may thus contribute to -cell auto-immune 
destruction. Islet cell auto-antibodies and auto-antibodies to insulin and glutamic acid 
decarboxylase (GAD65) are markers of immune- mediated -cell destruction and are found in 
over 80% of individuals with T1DM (Sandler, 1990).   
 
T1DM has a prolonged sub-clinical phase which may continue for several years prior to 
diagnosis; but the clinical onset of the disease usually occurs before the age of 30 and in 
many instances during childhood (Eisenbarth, 1986, Kulmala, 2003). When a genetic 
component is involved an external event, e.g. a viral infection, is considered to be the trigger 
for the autoimmune cascade which results in the near obliteration (greater than 90%) of the 
pancreatic beta-cell population (Haverkos et al., 2003, Kulmala, 2003, Dotta et al., 2007). In 
the initial stage -cell damage leads to a loss of first-phase insulin secretion, confirmed by 
use of an oral glucose tolerance test (OGTT), although normoglycaemia may persist despite 
the reduction in insulin levels (Bleich et al., 1990, Keymeulen, 2008). As the targeted assault 
on the beta cell progresses, the resulting impairment of insulin secretion eventually gives 
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rise to elevated plasma glucose. Once the autoimmune attack is at its height circulating 
levels of C-peptide become undetectable signifying loss of a functional beta-cell mass.  
 
A degree of pancreatic islet regeneration is thought to occur in Type 1 DM, notable during 
the initial period following diagnosis (referred to as the “honeymoon” period), but the 
continued presence of the autoimmune response prevents the recovery of adequate 
endocrine reserves.  As a consequence treatment of the condition relies mainly on the 
restoration of insulin levels by parenteral routes, or by the re-instatement of endogenous 
beta-cell mass by transplantation of a donor pancreas or more recently pancreatic islets 
(Pipeleers et al., 2008, Shapiro et al., 2000). 
 
1.3.2. Type 2 DM 
Type 2 diabetes (T2DM) has a higher prevalence than T1DM, and is a chronic, progressive 
metabolic disorder usually characterized by hyperglycaemia, hyperlipidaemia and insulin 
resistance. The widespread adoption of a sedentary western lifestyle has transformed the 
profile of T2DM from a disease of aging (with a later onset of development viz. beyond 40) 
to one which affects both the old and the relatively young. Rising in parallel with the 
increased incidence of obesity, T2DM is considered to be fuelled by the imbalance between 
food intake and energy expenditure (Franks et al., 2007) leading to a decrease in insulin 
sensitivity. A decrease in the adipose tissue protein adiponectin occurs with obesity which 
results in an increase in insulin resistance and -cell dysfunction (Bacha et al., 2004). The 
incidence of T2DM is also linked to low birth weight and poor nutrition and associated with 
8 
 
the deposition of amyloid plaques although the importance of these factors to the pathology 
of the condition remains unresolved. In experimental models of T2DM, the expression of 
islet -interferon is associated with the development of insulin resistance and glucose 
intolerance (Koivisto et al., 1989, Huang et al., 1994). As with T1DM, the underlying cause is 
also thought to involve some hereditary link with an increased risk of developing T2DM in 
individuals with close relatives (parents, siblings) affected by the disease, although no 
association between the disorder and specific HLA phenotypes or islet cell cytoplasmic 
antibodies has been demonstrated (Guven and Kuenzi, 1998). Insulin action is also impaired 
by nicotinic acid (McCulloch et al., 1991) and glucocorticoids (Gunnarsson et al., 1980).  
In addition to impaired insulin action, it is now appreciated that individuals with Type 2 
diabetes also experience significant -cell loss. Impaired glucose tolerance is associated with 
approximately 40% loss of -cell mass, and a 60-70% decline in -cell numbers is observed at 
the time of diagnosis of Type 2 diabetes, as found at post-mortem (Butler et al., 2003). It is 
likely that a combination of genetic factors and the adverse metabolic environment in which 
the islet resides leads to a gradual deterioration in  -cell function, leading to the loss of first 
phase insulin secretion and impaired/ delayed second phase insulin response. With the 
ensuing onset of hyperglycaemia, a diagnosis is made and oral hypoglycaemics are 
prescribed. It is thought that the success of this treatment i.e. restoration of 
normoglycaemia is due to the replenishment of functional  -cell mass and decreased insulin 
resistance, especially when combined with increased physical activity and weight loss. 
However, in many cases this therapy alone proves unsuccessful due to the progressive 
nature of the  -cell depletion and, as with T1DM, exogenous insulin therapy becomes the 
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only effective treatment option for the management of the condition and 
prevention/delayed progression of the associated complications. 
 
1.4. Management of DM 
The goals of therapy for T1 and T2 DM are to: 
 Eliminate symptoms related to hyperglycaemia 
 Reduce or eliminate the long-term microvascular and macrovascular complications 
 Allow the patient to achieve as normal a life-style as possible 
There are a number of pharmaceutical agents that are used in the management of DM; 
examples of the main groups are presented in the following sections.  
 
1.4.1. Management of T1DM 
As individuals with this form of disease lack endogenous insulin production, administration 
of exogenous insulin is essential for its management. 
 
(i)   Insulin Preparations 
Current human insulin and insulin analogues are manufactured using recombinant DNA 
technology although porcine and bovine insulins remain available. Human insulin analogues 
are further formulated to provide distinctive pharmacokinetics to mimic physiologic insulin 
secretion. Insulin preparations can be classified according to their plasma half-lives into  
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 Rapid-acting analogues e.g. insulin lispro, insulin aspart,  insulin glulisine 
 intermediate acting insulins e.g. isophane protamine insulin,  NPH  
 long acting insulin e.g. insulin detemir, insulin glargine 
 Biphasic preparations containing mixtures of rapid and intermediate acting 
insulin 
 
(ii) Insulin Regimens 
In all regimens, intermediate or long-acting insulins supply basal insulin, whereas the short 
acting provides prandial insulin. One commonly used regimen consists of twice-daily 
injections of intermediate-acting insulin mixed with short-acting insulin before the morning 
and evening meal. Such regimens usually prescribe two-thirds of the daily insulin dose in the 
morning (with about two-thirds given as intermediate insulin and one-third as short acting) 
and one-third before the evening meal (with approximately one-half given as intermediate 
and one-half given as short acting insulin). The drawback of such a regimen is that it enforces 
a rigid schedule on the patient, in terms of daily activity and the content and timing of meals. 
If the patient’s meal pattern or content varies or if physical activity is increased, 
hyperglycaemia or hypoglycaemia may result.  
 
Multiple component insulin regimens refer to the combination of basal insulin, pre-prandial 
short acting insulin and changes in short acting insulin doses to accommodate the results of 
frequent blood glucose monitoring. Such regimens offer the patient more flexibility in terms 
of life style and the best chance for achieving near normoglycaemia. This regimen is further 
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improved by use of continuous subcutaneous insulin infusion systems. Sophisticated insulin 
infusion devices (insulin pumps) can accurately deliver small doses of short-acting insulin 
(microlitres per hour) with additional doses to compensate increased glucose levels at 
mealtimes. Effective use of insulin pumps requires a health professional with considerable 
experience and frequent interactions with the diabetic management team. Insulin infusion 
devices present unique challenges, such as infection at the site of infusion (which is less 
common with the newer devices), hyperglycaemia because the infusion set becomes 
obstructed or diabetic ketoacidosis if the pump becomes disconnected or otherwise 
malfunctions.  
 
(iii) Disadvantages of insulin therapy 
Despite the combination of insulins employed or the route of their administration they can 
never perfectly mimic the profile of endogenous hormone release. Individuals with diabetes 
may at times experience episodes of hyperglycaemia (especially after meals) or conversely 
hypoglycaemia which can develop without warning and with a severity which may result in 
hospitalisation. 
 
Additionally, current insulin regimens have immediate access to the systemic circulation, 
whereas endogenous insulin is secreted into the portal venous system. Thus, exogenous 
insulin administration exposes the liver to sub-physiological insulin levels, affecting hepatic 
function and further disrupting glucose homeostasis (Lewis et al., 1996).  
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1.4.2. Management of T2DM 
The management of type 2 diabetes begins with changes to lifestyle, mainly to the 
nutritional intake and level of physical activity. If after 3 to 4 weeks of this approach the 
glycemic target is not achieved then pharmacological therapy is indicated.  
Pharmacological interventions include both oral glucose lowering agents (oral 
hypoglycaemics) and insulin. 
 
(i) Glucose lowering agents 
Oral glucose lowering agents are sub-divided into agents that increase insulin secretion, 
reduce glucose production/absorption or increase insulin sensitivity. 
 
 Insulin secretagogues (sulphonylureas) - stimulate insulin secretion by interacting 
with the ATP-sensitive potassium channel on the beta cell. These drugs are most 
effective in individuals with recent onset disease (<5 years), who tend to be obese 
with residual endogenous insulin production. Sulphonylureas increase insulin acutely 
and should therefore be taken shortly before a meal.  Sulphonylureas are generally 
well tolerated but have the potential to cause profound and persistent 
hypoglycaemia. Their hepatic metabolism and renal clearance preclude use in 
individuals with liver or kidney impairment. Examples of this group are tolbutamide, 
glimepride and glipizide.  
 
 Biguanides reduce hepatic glucose production and improve peripheral glucose 
utilisation. Although the precise mechanism(s) of action of the biguanides is not 
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known, reports suggest a role in reducing hepatic glucose production by inhibition of 
gluconeogenesis (Hundal and Inzucchi, 2003, Hundal et al., 2000). The occurrence of 
lactic acidosis poses the main risk to this group of compounds but is largely 
prevented by avoiding its use in patients with renal insufficiency, any form of 
acidosis, congestive heart failure, liver disease or severe hypoxia. A widely used and 
effective drug belonging to this class is metformin.  
 
 
 - glucosidase inhibitors diminish postprandial hyperglycaemia by delaying glucose 
absorption but do not affect glucose utilization or insulin secretion. This group is 
unique because it reduces the postprandial glucose even in individuals with type 1 
DM. Examples of this group are acarbose and miglitol. 
 
 Thiazolidinediones reduce insulin resistance by binding to the PPAR- (peroxisome 
proliferator-activated receptor-). Circulating insulin levels fall with the use of these 
drugs indicating a reduction in insulin resistance. These drugs are contraindicated in 
patients with liver disease or congestive heart failure (type III or IV). The major drug 
in this class, rosiglitazone has recently been withdrawn from use in the UK and 
Europe due to an increased cardiovascular risk associated with its use (Nissen and 
Wolski, 2010, Graham et al., 2010). 
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(ii)  Insulin therapy in type 2 DM 
Insulin should be considered as the initial therapy in type 2 DM, particularly in lean 
individuals or those with severe weight loss, in individuals with underlying renal or hepatic 
insufficiency that precludes oral glucose lowering agents, or in individuals who are 
hospitalized or acutely ill. Insulin therapy is ultimately required by a substantial number of 
individuals with type 2 DM because of the progressive nature of the disease and the relative 
insulin deficiency (due to -cell loss) that develops in patients with long standing diabetes.  
Treatment with insulin is not without its side effects.  Some of the disadvantages of insulin 
therapy have been mentioned in section 1.4.1. All of the adverse effects of insulin therapy 
can be potentially eradicated by the use of -cell replacement therapy.  
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1.5. Strategies to restore endogenous insulin secretion in T1DM 
1.5.1. Pancreas transplantation 
The restoration of endogenous insulin secretion by means of pancreatic transplantation has 
been carried out for many years. The first pancreatic transplant was conducted in 1966 at 
the University of Minnesota Hospital , USA (Kelly et al., 1967), since when, over 23,000 
pancreatic transplants have been reported through the International Pancreatic Transplant 
Registry. The different types of pancreatic transplants are: 
 Simultaneous pancreas and kidney transplant (SPK) - accounting for 80% of 
total performed 
 Pancreas after kidney transplant (PAK) – accounting for 10% of total 
performed 
 Pancreas transplant alone (PTA) 
 Simultaneous pancreas-kidney transplant from live donors 
There was an exponential rise in the number of pancreatic transplants performed worldwide 
in the 1990’s following which the number has reached a plateau. In Europe the number of 
transplants is decreasing, presumably due to better medical management of diabetes.  
 
Pancreatic transplantation is effective in maintaining normoglycaemia without the risks of 
inducing hypoglycaemia. In this respect it has clear advantages over the use of exogenous 
insulin. In addition, evidence suggests that it may prevent the long term complications of 
diabetes and reverse or alleviate pre-existing complications of the condition e.g. diabetic 
nephropathy (Fioretto and Mauer, 2011).  
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Pancreatic graft rejection is prevented by the use of chronic systemic immunosuppressive 
drugs which counteract the allogeneic reaction to the donor tissue. Both the short term and 
long term survival rates of pancreas grafts have improved as a result of technical advances 
and improvement of immunosuppressive regimens (Sutherland and Gruessner, 2007). SPK 
has the highest graft survival rate at 86% for the pancreas and 93% for the kidney at one 
year. The overall patient survival is over 95% at one year and 83% at 5 years post 
transplantation (Gruessner, 2011). Despite the high success rates, pancreatic transplantation 
is a major procedure which carries significant morbidity in comparison to pancreatic islet 
transplantation which offers a less invasive means of -cell replacement.  
 
1.5.2. Clinical Islet Transplantation 
Whole pancreas transplantation restores endogenous insulin production but, as individuals 
with T1DM usually have normal exocrine pancreatic function, islet transplantation 
represents a less invasive and thus more attractive option (Srinivasan et al., 2007). Islet 
transplantation is not only an option for the management of T1DM but has the potential, in 
the long-term, to become a curative procedure. According to the Diabetes Control and 
Complications Trial in 1993, intensive insulin therapy improved glycaemic control and 
outcomes in terms of secondary complication rates but at the cost of more frequent 
hypoglycaemic reactions in a significant proportion of patients (Srinivasan et al., 2007). The 
ultimate goal of islet transplantation is to liberate patients from the extensive and 
potentially life-limiting subcutaneous exogenous insulin regimen, whilst delivering sustained 
improvements to glycaemic control and thereby halting the progression of secondary 
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complications, chiefly end-stage organ failure. Current candidates for this procedure are 
limited to those with hypoglycaemic unawareness and those who already require 
immunosuppressive therapy due to a previous renal transplant (Ichii and Ricordi, 2009, 
Digon, 2009, Srinivasan et al., 2007).  
 
1.5.3. Historical Overview of Clinical islet Transplantation 
The concept of islet cell replacement pre-dates the discovery of insulin. Watson-Williams 
and Harshant performed a  xenotransplantation of sheep pancreas into a 15 year old boy in 
1893 who presented with the symptoms of diabetic ketoacidosis (Watson-Williams, 1894). 
Unprocessed sheep pancreatic grafts were transplanted subcutaneously in the patient’s 
chest and abdominal wall in the belief that extracts from this organ were able to counteract 
the clinical symptoms of glycosuria. Whilst the premise for the procedure was correct, 
supposedly based on the earlier findings of von Mering and Minkowski connecting 
pancreatectomy with the occurrence of glycosuria (Mering and Minkowski, 1889), the 
approach was bold and doomed to failure, with the patient succumbing to his illness 3 days 
later. Other attempts of pancreatic grafts, including human tissue from cadaveric donors 
were of minimal success, and following the groundbreaking research of Banting, Best, 
Macleod and Collip and the subsequent isolation and purification of insulin in 1921 the 
concept of islet replacement was virtually forgotten.  For many years insulin remained the 
only treatment for T1DM, prolonging the lives of those affected. In time, as these patients 
lived longer it became evident that insulin was unable to counter the life-threatening 
secondary complications of diabetes to which many diabetic individuals did, and still do, 
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eventually succumb.  In response, attempts to perform a vascularised pancreas 
transplantation were made (Kelly et al., 1967), and as a natural progression the possibility of 
replacing the islets alone was explored. 
 
Interest in islet replacement therapy was stimulated by the results of pancreatic islet 
autografts. A report in 1980 by Najarian et al described the outcome of a series of 10 
patients who underwent total pancreatectomy and subsequent autologous islet 
transplantation for chronic pancreatitis; 5 patients experienced varying periods of insulin-
independence (Najarian et al., 1980). In another study later that year  (Largiader et al., 
1980), 4 patients had combined renal and pancreatic transplantation in which pancreatic 
micro fragments were implanted into the spleen of which one  remained insulin-free up to 
91/2 months following transplantation. These autografts were considered as “proof-of-
concept” for islet cell replacement and were followed by numerous reports of allogeneic 
islet transplantation in humans. However, the overall success rate from these studies in 
terms of insulin independence at 1 year was less than 10% (Srinivasan et al., 2007). Indeed, 
of the 267 allografts transplanted between 1990 and 2000, only 12.4% resulted in insulin 
independence for periods of more than one week, and only 8.2% remained insulin 
independent for more than one year (Shapiro et al., 2000).  
 
A paradigm shift occurred in 2000 with the publication of a trial of clinical islet 
transplantation conducted by researchers in Canada (Shapiro et al., 2000). Seven patients 
with a history of Type 1 diabetes of over five years, erratic blood glucose measurements 
despite being on insulin therapy and who experienced recurrent severe hypoglycaemia with 
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coma or metabolic instability received multiple infusions of allogeneic islets  into the liver via 
the portal vein and were maintained under a glucocorticoid-free immunosuppression 
regimen (sirolimus, tacrolimus and daclizumab). All seven patients became insulin 
independent and remained so at a median follow-up of 11.9 months (range, 4.4 to 14.9) 
(Shapiro et al., 2000). The protocol (now widely referred to as The Edmonton Protocol) was 
subsequently conducted as an international, multicentre trial in 2006 at nine locations to 
evaluate its reproducibility (Shapiro et al., 2006). Thirty six patients who met the required 
criteria were enrolled onto the study and the results showed that at 1 year after 
transplantation, 44% of the patients were insulin independent and 31% of these patients 
remained insulin independent at 2 years post transplantation. The results at 5 years 
indicated attrition of graft function with time as only 10% remained insulin-free.  However, 
persistent graft function even without insulin independence appears to provide protection 
against severe hypoglycaemia and to improve  glycaemic stability with the potential, 
therefore, to limit the progression of secondary complications (Ryan et al., 2005).  
 
1.6. Current clinical outcomes for Clinical Islet Transplantation 
According to the latest reports from the Collaborative Islet Transplant Registry (CITR, 2011), 
there have been 571 allogeneic islet transplant recipients between 1999 and 2009 who have 
received 1072 infusions from 1187 donors. 481 of these transplants were islet alone whilst 
90 were islets with or after kidney transplantation.  
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Insulin independence was seen in 65% of recipients in the first year post first infusion and by 
year 2 this was 75%.  Despite loss of insulin independence over long-term follow up, the 10 
year data indicates overall increase in graft survival rates, presumably due to further 
refinements to the technique. Thus, the insulin independence period was significantly 
greater in the graft recipients treated during the period 2004-2007 compared to those 
receiving implants from 1999-2003. The rates of graft survival can differ with rates of 40% to 
80% at 5 years being recorded in the registry.  Glycosylated haemoglobin (HbA1c), an 
indication of glycaemic control, is reduced in islet transplant recipients and in addition a 
decreased incidence of severe hypoglycaemia is observed even in those recipients who 
return to insulin therapy and have a partially functioning graft.  
 
1.6.1. Risks of Islet Transplantation 
Amongst the 571 islet graft recipients, 29 incidences of malignant neoplasms have been 
observed involving 27 patients. There have been 18 reported deaths for islet recipients 
resulting from infection (5), cerebral haemorrhage (3), cardiovascular (2), acute respiratory 
distress syndrome (1), diabetic ketoacidosis (1), lung carcinoma (1), multi-organ failure (1), 
acute toxicity (1) and unknown causes (3). 
 
The overall conclusions drawn from the CITR report suggest that islet transplantation is an 
evolving treatment option for diabetes, which continues to show improved long-term 
benefits. The technique is minimally invasive with few infusion related complications and a 
comparatively low incidence of cancer and death.  
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1.7. Factors influencing Islet Transplant Availability and Outcome 
Despite the success of the Edmonton Protocol and an increasing interest in the field of 
pancreatic islet transplantation, the limited availability of donor organs and progressive loss 
of graft function adversely restricts the wider use of this approach for the management of 
DM. The factors most likely to limit wider clinical application include: 
 
 Shortage of donor organs 
 Injury to the islet due to the isolation process 
 Impact of the site of transplantation 
 Risk of recurrent autoimmune destruction 
 Use of chronic systemic immunosuppression 
 
 
 
 
 
 
 
 
 
22 
 
1.7.1 Shortage of donor supply 
 
The marked disparity between potential graft recipients and available donor organs limits 
the clinical application of all major transplant therapies, and this is also the case in islet 
transplantation. Whilst it has been reported that only 50% of available cadaveric pancreata 
enter the donor pool (McCall and James Shapiro, 2012), it is widely accepted that the ever 
increasing number of patients suffering with T1DM will always far exceed the number of 
clinical islet transplants that may be carried out. The situation is exacerbated by the fact 
that, at present, whole pancreas transplantation is viewed as the preferred treatment option 
for re-instating endogenous insulin reserves, further reducing the number of organs 
available for islet replacement therapy. Also each graft recipient may require islet infusions 
from up to 3 pancreata to achieve insulin-independence, placing a greater burden on the 
restricted donor pool.  
 
Widespread adoption of tissue/cell-based treatments for diabetes will, therefore, rely 
heavily on the successful development of strategies to either obtain or generate large 
numbers of appropriately functional, readily transplantable and ideally immune-tolerant -
cells. Current research in the field has, to date, failed to identify a reliable source of 
surrogate -cells which adequately substitute for those obtained from cadaveric donors. At 
present the major lines of investigation include the potential use of xenogeneic islets, human 
embryonic stem cells (hESC) and human induced pluripotent cells (iPSC) which are fully 
differentiated somatic cells with the capacity for re-programming to a -cell phenotype. 
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In regard to xenogeneic transplantation, research has focussed on the use of porcine islets 
due to their physiological similarity to human islets. Pre-clinical trials are presently being 
conducted at several centres using encapsulated porcine-derived islet cells with promising 
preliminary results (Hering et al., 2006).   
 
Several groups have reported on the in-vitro differentiation of embryonic stem cells, 
adopting defined culture protocols in an attempt to produce stable insulin-secreting cells 
(Kroon et al., 2008). However at present relatively low numbers of cells have been generated 
by these methods and those produced lack the characteristics of fully mature and 
physiologically appropriate insulin-secreting cells; well-defined “proof of concept” studies 
relating to their ability to sustainably reverse hyperglycaemia are yet to be performed.  
Furthermore, the use of cells from embryos continues to raise objections on ethical grounds.  
 
Human induced pluripotent stem cells (iPSC) circumvent the controversy associated with the 
use of embryonic stem cells and furthermore offer the possibility of generating patient- 
specific cells for use in regenerative therapy. Indeed, certain reports suggest the feasibility of 
deriving iPSC from the fibroblasts of diabetic individuals which are subsequently 
reprogrammed towards a pancreatic lineage (Maehr et al., 2009). However, the technique is 
at present expensive and inefficient and the use of viral vectors and/or oncogenic factors will 
always be a cause for concern.  
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Thus, whilst all the above-mentioned techniques may, in time, represent alternatives for use 
in clinical islet transplantation, at present they remain largely experimental and are not likely 
to contribute significantly to the wider use of cell replacement therapy in the near future.  
 
1.7.2. Impact of isolation process 
Islet isolation is imperative to clinical islet transplantation but the process has deleterious 
effects on islet viability.  It is generally considered that the functions of the endocrine 
pancreas are closely related to its micro-architecture and therefore metabolic control 
depends not only on the integrity of the islets but also on the interaction of different cell 
types within and around the islet (Hopcroft et al., 1985). Disruption of the anatomical 
relationship between different pancreatic cell populations as a consequence of the isolation 
process is therefore thought to contribute to loss of islet function. Additionally, the pancreas 
has a complex vascular and neuronal network that is destroyed during the islet isolation 
process and is another factor contributing to the loss of functioning islets and subsequent 
graft failure (Correa-Giannella and Raposo do Amaral, 2009).  Ischaemia of the islets 
occurring during the isolation process causes further insult (Dionne et al., 1993). It has been 
suggested that the pre-transplant culture of islets may lead to their rehabilitation and also 
allow time to confirm cell viability and sterility. The original Edmonton Protocol involved the 
infusion of freshly isolated islets (Shapiro et al., 2000) but in subsequent studies published by 
the Edmonton group and others islet culture has been shown to enhance islet morphology 
and overall viability (Murray et al., 2005) despite a slight decline in overall beta cell mass (Kin 
et al., 2008).  
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1.7.3. Site of transplantation 
 Data from the Islet Transplant Registry indicates that 90%  of clinical islet transplantations 
performed worldwide involve portal infusion into the liver (Merani et al., 2008).  Historically 
the liver has been viewed as a suitable site for transplantation based on evidence from 
experimental studies such as those described by Kemp et al showing that fewer numbers of 
islets are required to reverse hyperglycaemia in rats when located in the liver compared with 
intraperitoneal and subcutaneous sites (Kemp et al., 1973). The site is advantageous mainly 
for two reasons: access to the portal vein can be achieved relatively easily under ultrasonic 
or fluoroscopic guidance (Owen et al., 2003, Goss et al., 2003) and the hepatic site permits 
physiological delivery of insulin as pancreatic  cells secrete the hormone directly into the 
portal circulation (Kemp et al., 1973, van der Windt et al., 2008).  
 
Despite the advantages described above there are several reasons to view the liver as a less 
than hospitable site, contributing to the poor long-term outcome of islet transplantation 
when compared to that of whole organ. The oral immunosuppressive agents used to prevent 
graft rejection are present in higher concentrations in the portal blood (prior to the first-pass 
effect), and are known to have toxic effects on transplanted islets (van der Windt et al., 
2008). The portal route places the islets in direct contact with blood making them vulnerable 
to the ‘instant blood mediated inflammatory reaction’ (IBMIR) which is characterised by 
activation of the coagulation cascade resulting in significant cellular damage and a profound 
reduction in functional graft mass. Also an adaptive immune response may be induced as a 
result of the early inflammatory changes brought about by resident macrophages (Kupffer 
cells). Chronic hyperglycaemia results in oxidative stress in tissues due to the induction of 
26 
 
reactive oxygen species. Islets in the liver are exposed to high glucose concentrations in the 
portal blood and as a result are vulnerable to such an assault (Robertson and Harmon, 2006).  
Additionally, toxins absorbed by the gastrointestinal tract travel to the liver via the portal 
vein and thus expose the islets to these potentially harmful substances (Robertson, 2004). 
Hepatically located islets demonstrate a  lower oxygen tension compared to native islets 
(Carlsson et al., 2001) and disruption of hepatic homeostasis may occur due to a loss of 
counter regulation mechanisms whereby islets in the liver fail to recognise the metabolic 
cues to produce glucagon in response to hypoglycaemia (Paty et al., 2002b).  Finally, relating 
to diagnosis and cause of graft failure, taking biopsies of transplanted islets after intraportal 
transplantation is extremely difficult because the islets randomly distribute throughout the 
liver sinusoids, parenchyma and portal vascular system; efforts to confirm loss of functional 
mass by histological means is therefore hampered.  
 
As a consequence to the limitations of the hepatic approach, alternative sites for islet 
transplantation are being examined including subcutaneous sites which offer easy access for 
monitoring and graft retrieval. However, subcutaneously implanted islets present insulin to 
the liver via the systemic circulation rather than the preferred portal route, and with time 
are thought to become necrotic, indicative of reduced oxygenation and nutrition supply 
(Shapiro et al., 2000). The gastric submucosa is also being considered as a substitute, 
offering endoscopic islet delivery, and preliminary experimental studies in large mammals 
have yielded some promising results (van der Windt et al., 2008). Other sites which have 
been considered but largely rejected for clinical use include the sub-renal capsule (more 
generally used in experimental transplant studies), the spleen (previously used for islet auto-
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grafts) the pancreas and the omental pouch which offer portal insulin delivery.  
Intramuscular sites for implantation have been proposed following a report of autologous 
islet transplantation into the brachioradialis (forearm muscle) of a young girl treated for 
hereditary pancreatitis. In this instance the graft was fully functional after 2 years (Rafael et 
al., 2008) but this site is associated with significant leucocytic infiltration (Merani et al., 
2008). 
 
1.7.4. Recurrence of the auto-immune response 
The mechanism(s) underlying auto-immune-mediated destruction of islet beta cells are not 
fully understood with existing knowledge being derived mainly from post mortem studies, 
tissue taken from pre-diabetic and recently diagnosed patients and experimental models of 
diabetes. It is generally accepted that both CD4+ and CD8+ T-cells are involved in the process 
of islet insulitis but their relative contributions to -cell destruction are poorly understood, 
as are the precise identities of the molecular effector mechanisms which mediate cell death. 
In addition to T-lymphocytes a myriad of other immune cells including macrophages, 
dendritic cells (DC) and B lymphocytes work together to induce and sustain the immune 
assault. Antigen-presenting cells, such as macrophages and DC are the first cells to initiate a 
response and recruit T-cells via the release of chemokines which infiltrate the islet, closely 
followed by natural killer cells (NK) and B lymphocytes. Infiltrating macrophages serve to 
activate cytotoxic CD8+ cells which are known to execute -cell destruction by the release of 
cytolytic agents; granzymes and perforins. CD4+ T-cells may also act indirectly through B-cell 
activation and the generation of complement fixing antibodies. The process is further 
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stimulated by pro-inflammatory cytokines released by macrophages including interleukin 
(IL)-12 which activate Th1-type CD4+ T-cells. In turn activated CD4+ T-cells secrete IL-2, 
interferon-, and TNF- which maximise CD8+ activation. Reactive oxygen species such as 
nitric oxide may also be released by activated macrophages at the site of islet infiltration. 
Additionally, the Fas-Fas Ligand pathway has also been implicated in CD8+ T-cell mediated 
cell death although it has also been suggested that this pathway may play a role in graft 
tolerance (Yolcu et al., 2011) presumably by directing the apoptosis of Fas bearing T-cells. 
 
In addition to the action of T-cells B lymphocytes are also involved in the pathology of T1DM. 
Thus, as part of the auto-immune response anti-islet cell antibodies are produced which 
specifically target the insulin-secreting -cells.  These auto-antibodies persist in many 
individuals with T1DM even when all of the insulin-containing cells have been destroyed. 
Replacing these with islets from a donor re-introduces the target antigen, albeit now from an 
allogeneic source. It is therefore possible that graft recipients will experience a recurrence of 
the auto-immune response targeting the transplanted tissue in addition to the allo-immune 
response that would occur in the absence of immunosuppressive therapy. This has been 
demonstrated in pancreas transplantation as reported by Sutherland et al (Sutherland et al., 
1984, Sibley et al., 1985, Sutherland et al., 1989). In this series of studies living donor 
pancreas transplants between HLA-identical twins and siblings performed in the absence of 
immunosuppression were characterised by a rapid return of hyperglycaemia and evidence of 
insulitis but no indication of overt acute graft rejection.  It was concluded that the damage 
was caused due to recurrence of the auto-immune response, supported by the detection of 
circulating islet cell antibodies corresponding with the return of hyperglycaemia. High islet 
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cell antibody titers may also be detected in pancreas and islet graft recipients, correlating 
with poor graft function (Thivolet et al., 2000).  
 
  
1.7.5. Chronic Systemic Immunosuppression – current regimens versus adverse effects 
Immunosuppression in clinical islet transplantation aims to reduce two major immune 
responses likely to be directed towards the graft; (i) the recurrence of the auto-immune 
destruction of -cells as described above and, (ii) specific alloantigen mediated rejection. 
Whilst most immunosuppressive regimens exhibit a degree of success in achieving these 
aims, they bring with them a range of adverse effects which compromise the health of both 
the recipient and the islet graft.   
 
Long term immunosuppression is associated with a deterioration of pre-existing morbidity 
(renal and liver impairment) (Hafiz et al., 2005, Ryan et al., 2005) and the development of 
new complications (rashes, ulcerations, organ toxicity, infections and tumours) which may 
be life-threatening (Ryan et al., 2004). Prior to the Edmonton Protocol, islet transplant 
protocols relied heavily on steroid-based immunosuppression consisting chiefly of antibody 
induction with an anti-lymphocyte globulin combined with cyclosporine, azathioprine and/or 
glucocorticoids (Shapiro et al., 2000) many of which were in themselves diabetogenic. The 
Edmonton Protocol heralded the start of the “steroid-free” era with induction using a 
monoclonal antibody against IL-2 receptor (Daclizumab), and maintenance with a 
combination of sirolimus (rapamycin – target 7-10g/l) and tacrolimus (FK506 – target 3-6 
g/L) (Ichii and Ricordi, 2009, Shapiro et al., 2000) which is thought to have contributed to 
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improved clinical outcomes (i.e. 54% of recipients insulin-independent at 3years). Despite 
this success, there remain major problems associated with the new immunosuppressive 
drugs employed. Reports suggest that sirolimus frequently causes dyslipidaemia, 
myelotoxicity, hypertension and increases the occurrence of skin rashes, oral mucosal 
ulceration and symptomatic small bowel ulceration (Molinari et al., 2005).  Less frequent 
side effects of sirolimus include interstitial pneumonitis and proteinuria which resolve on 
withdrawal (Digon et al., 2003, Senior et al., 2005). Tacrolimus is diabetogenic and its use is 
associated with neurotoxicity, nephrotoxicity (Gruessner, 1997), and less frequently severe 
atopic dermatitis and alopecia (Ponte et al., 2007a, Zuk et al., 2011). Recent reports suggest 
that premenopausal female islet recipients using a sirolimus and tacrolimus 
immunosuppression regimen have a high incidence of developing ovarian cysts and other 
gynaecological abnormalities (Del Olmo Garcia et al., 2011, Alfadhli et al., 2009). This drug 
combination has also been linked to an increased incidence of lymphoma but no definitive 
relationship has been established (Shapiro and Shaw, 2007), and may also result in abnormal 
renal and liver function tests, haematological abnormalities and electrolyte imbalance. 
Mycophenolate Mofetil (MMF – 1000mg/BID) has proven to be an effective alternative to 
tacrolimus and/or sirolimus and its use reduces the occurrence of adverse reactions (Senior 
et al., 2005, Hafiz et al., 2005, Hering et al., 2005). Since the Edmonton Protocol was first 
introduced, this drug along with newer alternatives to the standard induction therapies i.e. 
alemtuzumab or rabbit anti-thymocyte globulin have been employed demonstrating similar 
results to that seen with the standard regimen on early follow-up. 
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In time it may be possible to minimize the side effects associated with chronic systemic 
immunosuppression but it is less likely that their impact on graft function can be totally 
eliminated. As previously mentioned the hepatic location of transplanted islets places them 
squarely in the path of high concentrations of orally-administered immunosuppressive drugs 
which has direct relevance to long-term islet graft survival. MMF and tacrolimus are both 
associated with hyperglycaemia and have been shown to  inhibit glucose-stimulated insulin 
release in both primary islets and insulin-secreting cell lines (Paty et al., 2002a). Tacrolimus is 
considered to directly decrease insulin synthesis and secretion, as evidenced by loss of 
secretory granules and reduced -cell density. Reports also suggest that tacrolimus causes 
dose-dependent and reversible cytoplasmic swelling, and vacuolization of islets leading to 
apoptosis which is reversed if the drug is discontinued (Drachenberg et al., 1999). Sirolimus 
inhibits-cell proliferation and prevents islet regeneration (Zahr et al., 2007, Niclauss et al., 
2011) also having a deleterious effects on islet engraftment and function (Marzorati et al., 
2009). Of note, sirolimus has been shown to decrease islet cell viability following implantation 
by both a direct effect on islet integrity and by preventing graft re-vascularisation through 
inhibition of vascular endothelial growth factor (VEGF) production (Laugharne et al., 2007, 
Cross et al., 2007). It is evident that the chronic use of immunosuppressive drugs may not be 
compatible with long-term -cell survival in clinical islet transplantation and alternative 
approaches to graft immuno-protection must be devised. 
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1.8. Strategies to Circumvent Chronic Systemic Immunosuppression 
Non-pharmacological methods of preventing islet allo-graft rejection seek to eliminate the 
harmful consequences of chronic systemic immunosuppression both for the recipient and 
the islet graft. This field has grown alongside that of clinical islet transplantation itself and, 
with an increased understanding of immune-tolerance, new and more sophisticated means 
of delivering graft immune-protection have been developed and clinically evaluated. 
 
1.8.1. Immune-Isolation: Islet encapsulation to reduce allograft recognition 
To date, the most widely explored technique for the immune-protection of grafted cells is 
micro-encapsulation; the process of embedding islets within a semi-permeable membrane 
(de Vos et al., 2010, Beck et al., 2007, de Vos et al., 2002, Gray, 2001). The process aims to 
minimize the allo- immune response, chiefly by reducing the ability of the host to recognise 
surface antigens expressed by the graft. Coating of the islets with a biocompatible material 
also serves to provide a physical barrier between the host immune system and the 
transplanted cells, thus preventing direct cellular attack. The masking of surface antigens 
also makes encapsulation relevant to the field of xenotransplantation; clinical trials are 
currently underway to determine the efficacy of encapsulated porcine islet grafts which have 
lent insight into the potential of this technology (Valdes-Gonzalez et al., 2010, Valdes-
Gonzalez et al., 2007, Valdes-Gonzalez et al., 2005). 
 
Whilst the theory underlying micro-encapsulation is valid, in practise it has posed challenges, 
particularly in terms of the materials used. In order to maintain capsule integrity and reduce 
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the possibility of fibrotic overgrowth encapsulation materials must be biocompatible, robust, 
endotoxin-free and of a sufficient permeability (porosity) to permit access of vital nutrients 
and oxygen and the release of endocrine hormones, whilst preventing passage of immune 
cells. In early studies most capsule materials failed to supply the highly metabolic islet with 
sufficient nutrients and oxygen conducive to its survival and graft-derived cytokines escaped 
the capsule to provoke an inflammatory assault (Schrezenmeir et al., 1994, Zekorn et al., 
1993) both leading to a significant loss of islet viability. However, more recent improvements 
including the modification of materials used (e.g. increasing the purity of alginates, poly-
lysine, poly(ethylene glycol) (PEG) diacrylates) has led to enhanced islet transplant outcomes 
as demonstrated in animal studies (Figliuzzi et al., 2006, Langlois et al., 2009).  
 
A further major limitation associated in the technique of encapsulation relates to capsule 
size which dictates clinical application. Thus, at present, infusion of microencapsulated islets 
into the liver is precluded by the high risk of venous occlusion and therefore the technique is 
not compatible with the current clinical islet transplantation protocol.  Alternative suitable 
sites are being evaluated in pre-clinical studies; the peritoneal cavity would be able to 
accommodate larger transplant volumes but may be unfavourable in terms of its poor 
potential for graft re-vascularisation. In contrast the omental pouch receives a significant 
arterial supply, provides appropriate surgical access and displays unique reconstructive 
capabilities (Berman et al., 2009). 
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Encapsulation technology may prove most effective when combined with short-term, low-
dose immunosuppression which has been shown to reduce capsular overgrowth. Of interest, 
the use of sirolimus and belatacept (a CD28-CD154 co-stimulation blockade regimen) has 
proven effective in preventing the rejection of encapsulated porcine islets transplanted into 
primates, an advance for the use of xenografts (Cardona et al., 2007, Cardona et al., 2006). 
Nano-capsule devices, formed with multiple layers of biocompatible polymer applied directly 
to the islet surface markedly reduce bead diameter thus circumventing the problem of 
restricted nutrient and hormone transfer. When impregnated with a low-dose 
immunosuppressive agent (e.g. cyclosporine) nano-capsules provide camouflage to 
allogeneic islets whilst actively creating a local site of immune-privilege (Lee et al., 2006).  
This process has obvious potential but is technically challenging and incurs significant beta 
cell loss which is especially critical in light of the shortage of suitable organs for use in clinical 
islet transplantation.  Additionally, it is not yet proven that the nano-capsules have sufficient 
integrity to withstand the transplantation procedure itself, or to remain intact long-term at 
the implant site. Energies are now focussed on standardizing the methods for micro-and 
nano-capsule production including the grade of the components, capsule size, diffusivity, 
permeability, and structural integrity in an attempt to advance their clinical effectiveness.  
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1.8.2. Immune-modulation: Anatomical immune-privileged sites and tissues which support 
allogeneic transplantation 
The concept of immune-privilege as proposed by Peter Medawar (Medawar, 1948), has long 
been the fascination of immunologists and transplant surgeons. Anatomical locations within 
the body including the eye, testis, pregnant uterus and brain exhibit a rare ability to evade 
the actions of the immune system and, as such are considered to hold the key to successful 
allograft transplantation.  These sites are considered to be immune-privileged as implanted 
foreign tissue, placed for example in the anterior chamber of the eye, is capable of survival 
and thus fails to abide by the normal rules governing immune rejection (Medawar, 1948).  To 
date, a clear explanation as to the special status of these sites has not been fully elucidated 
although the lack of lymphatic drainage and the presence of a physical blood:tissue barrier 
are considered to be likely mechanisms, creating "immunological ignorance” (Medawar, 
1948). Whilst these physical features may have some significance, especially in the eye, it is 
now known that immune-privileged sites remain fully accessible to immune cells and that a 
number of physical and chemical properties work in concert to bring about the diminution of 
the immune response seen in these tissues. The net effect is down-regulation of the immune 
system by (a) alteration of antigen accessibility (b) modification of antigen presentation, and 
(c) modulation of immune cell activity at the site of the graft. The term immune-privilege is 
now associated both with anatomical sites e.g. areas of the body able to accommodate an 
allogeneic graft in the absence of systemic immunosuppression, and tissue i.e. groups of 
cells which survive as allogeneic grafts at anatomical sites where normal tissues would 
immediately be rejected. 
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Immune-privileged tissues generally have common features which underlie their inertness 
including the lack of expression of class I and class II MHC molecules and the expression of 
class Ib molecules (e.g. HLA-G in the placenta and amniotic membrane). Some tissues also 
demonstrate unique physical properties where their parenchymal cells are held together by 
an extensive series of tight junctions as is the case for Sertoli cells (SC) and retinal pigmented 
epithelial cells. Additionally, cells exhibiting immune-privilege characteristics have been 
shown to secrete a myriad of immunosuppressive cytokines including interleukin (IL) 4, IL-10 
and TGF-Furthermore, the constitutive expression of the pro-apoptotic protein Fas Ligand 
(FasL) has also been reported in a number of immunomodulatory tissues including testis, 
retina and placental membranes. 
 
In the context of clinical islet transplantation anatomical sites which offer a degree of 
immune privilege would be beneficial.  Sites such as the thymus and testis have been 
proposed as implantation sites where islets experience a degree of immune-protection. As 
the thymus is the site for T-cell maturation, including negative selection, the thymic infusion 
of islets could theoretically expose developing T-cells to islet alloantigens, the net result 
being deletion of allogeneic islet-specific T-cells (Merani et al., 2008).  This would be a 
significant immunological advantage, yet experimental studies indicate that implantation to 
the thymus requires a large number of islets  if glucose homeostasis is to be achieved (Levy 
et al., 2002).  
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The testis provides a second immune-privileged site for islet infusion where experimental 
studies demonstrate that intra-testicular islet transplantation results in decreased memory 
CD8+ T-cell infiltration to the site of the graft and induces more antigen-specific CD4+CD25+ 
regulatory T-cells (Nasr et al., 2005). The use of Sertoli cells for co-transplantation with islets 
is seen as a natural progression to intratesticular islet transplantation and has been 
enthusiastically explored both experimentally and in small clinical trials (Yin et al., 2009, 
Valdes-Gonzalez et al., 2007, Valdes-Gonzalez et al., 2010, Valdes-Gonzalez et al., 2005, Kin 
et al., 2008) although some controversy surrounds the clinical efficacy of this approach 
(Wang et al., 2005, Sykes et al., 2006, Sykes and Cozzi, 2006). More recently the anti-
inflammatory and immuno-modulatory properties of  bone marrow derived mesenchymal 
stromal cells have been harnessed for clinical use; notably for the treatment of graft versus 
host disease and autoimmune arthritis, and are now being evaluated for  ability to prevent 
allograft rejection in experimental islet transplant models (Duprez et al., 2011, Ding et al., 
2010). It is evident that being able to create immune-privilege either in or within the vicinity 
of the islet graft would be a major positive step towards improving the clinical outcome and 
therefore applicability of islet transplantation. The use of “bystander” immunosuppression 
as suggested by the co-transplantation studies with Sertoli and mesenchymal stromal cells 
add credence to this approach; its widespread adoption awaits greater understanding of the 
underlying mechanism(s) for the observed immuno-regulatory effects and detailed studies 
on the long-term efficacy and safety. 
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1.8.3. Human Amniotic Epithelial Cells 
Recent studies suggest that human foetal membranes provide an alternative source of cells 
which may also induce localised immunosuppression (Wolbank et al., 2007, Parolini et al., 
2008) but without the limitations of availability and standardisation experienced with Sertoli 
and mesenchymal cells. Human amniotic membrane has current clinical use as a temporary 
dressing for wounds, burns and as an adjunct to ophthalmic surgery (Sheridan and Moreno, 
2001, Mermet et al., 2007, Gomes et al., 2005) where it is grafted without rejection. The 
cells comprising its inner lining, amniotic epithelial cells (AEC), possess innate anti-
inflammatory and immunomodulatory characteristics; secreting soluble factors with the 
ability to inhibit local activation/migration of neutrophils and macrophages (He et al., 2008, 
Li et al., 2006a, Tseng et al., 2004, Li et al., 2005) and suppress the activation and graft-
destroying actions of immune T-cells (Wolbank et al., 2007, Li et al., 2005). Human AEC also 
express soluble mediators associated with the creation of immune-privilege including FasL, 
HLA-G, and IL-10 (Parolini et al., 2008, Wolbank et al., 2007, Bertelli and Bendayan, 2005, 
Lefebvre et al., 2000). Preliminary data indicates that AEC exhibit a potent and robust 
suppression of mitogen-induced lymphocyte proliferation whilst exhibiting immune-
inertness (Parolini et al., 2008, Wolbank et al., 2007). Their ability to extend this immune-
privilege to other, co-transplanted cells (viz. as observed with Sertoli and mesenchymal cells) 
forms the basis of this thesis. 
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1.9. Aim of this Study 
It is widely considered that islet transplantation offers a unique opportunity to treat T1DM 
and reduce the incidence of its debilitating secondary complications. The results of several 
clinical trials including those performed in the UK suggest that a degree of metabolic stability 
is achieved by islet transplantation which far exceeds that attainable using even the most 
strict exogenous insulin regimen. However, the widespread use and long-term survival of the 
islet graft is hampered by a number of factors, including the impact of chronic 
immunosuppressive drug use. 
 
The unique feature of islet transplantation compared to whole organ treatments is the 
relatively small volume and cellular nature of the graft which provides the opportunity to 
use a more defined/discrete and novel means of immune-protection. Microencapsulation in 
a semi-permeable membrane to evade the immune system is one such approach. Equally 
credible is a method of actively suppressing the immune system at the site of the grafted 
cells – effectively creating localised immune-privilege. 
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1.9.1. Hypothesis 
Current literature suggests that human amniotic epithelial cells possess certain unique, 
inherent immunosuppressant properties which may be exploited to provide a biocompatible 
method of modifying the immune response. This study proposes that these properties may 
be extended to provide immune protection to transplanted islets thereby reducing the risks 
of chronic systemic immunosuppression faced by those undergoing islet transplantation. The 
present study investigates the immunomodulatory properties of human amniotic cells and 
their ability to alter the immunogenicity of islet cells as observed in an in vitro co-culture 
system.  
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Chapter 2:  HUMAN ISLET ISOLATION AND ASSESSMENT OF 
BETA ()-CELL FUNCTION IN THE POST-ISOLATION SETTING 
 
2.1. Introduction-Isolation of Pancreatic islets for Research Purposes 
The isolation of functionally viable human islets is a prerequisite of both successful clinical 
islet transplantation and transplant-related research.  The technique of islet isolation has 
evolved over the last 5 decades, culminating in the development of a semi-automated 
method, capable of providing high quality, clinical grade islets, suitable for use in 
transplantation.  Of note, improvements to the method of organ procurement, the design of 
a refined collagenase enzyme blend (Liberase, Roche), development of a ductal route of 
enzyme delivery and custom-made apparatus for organ digestion (The Ricordi Chamber) 
ensure complete pancreas dissociation. Furthermore, modifications made to the COBE 2991 
cell processor have enabled its effective use in islet purification using a linear continuous 
density gradient.   Yet despite these advances, successful islet isolation using the semi-
automated method still relies heavily on the procurement of pancreata which meet strict 
criteria both in terms of donor characteristics and the condition of the organ at the time of 
retrieval.  Added to this, the relative lack of multi-organ donors in the UK means that all 
pancreata which fulfil these criteria are automatically assigned to the clinical pancreas and 
islet transplantation program with only those which fail to do so being made available for 
research.    
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The islet research laboratory in Worcester, along with others, have devised manual methods 
of islet isolation whereby additional interventions can be made for the unpredictable 
variables associated with marginal organs, including multiple sampling during the digestion 
phase and the use of discontinuous gradients for separation of islets. Interestingly, such 
manual methods use fewer resources yet are still capable of producing islet yields of up to 
300,000 islets per isolation which compare favourably with that achieved using the semi-
automated method (400-500,000 islets per isolation). Furthermore, manual islet isolation 
allows researchers to fully utilize organs rejected for clinical transplantation, producing 
viable islets in 90% of isolations attempted which contrasts with the semi-automated 
method where the main islet isolation centres have reported successful clinical grade islet 
isolations from 25-75% of pancreata procured (Paget et al., 2007). These modifications have 
enabled viable retrieval of islets from sub-optimal donor pancreata thus making best use of 
scarce human tissue to further advance the field of islet transplantation and other areas of 
diabetes research. 
 
Aim of the Chapter 
The following is a detailed description of the manual method of islet isolation employed in 
this study; presenting data regarding the morphological and functional characteristics of the 
islet preparations obtained and discussing their suitability for use in research. 
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2.2. Materials and Methods  
2.2.1 Pancreas procurement  
Human pancreata were obtained through the UK Human Tissue Bank (UKHTB), De Montfort 
University, Leicester, from multi-organ donors. These organs are deemed unsuitable for 
clinical use (whole organ or islet transplantation) due to the donor exclusion criteria applied 
or because of the physical characteristics of the organ (e.g. fatty, fibrous, damage to the 
capsule or associated vessels). Organs were normally referred within 10 hours of retrieval. 
For the purpose of the present study the following donor criteria were considered when 
accepting a pancreas for the purpose of islet isolation. 
 
 Age- In most instances organs were accepted from donors aged between 18 
and 65. In our experience pancreata from younger donors (i.e. < 15 yrs), 
whilst yielding islets with superior function, routinely produce a lower yield 
due to the difficulty in separating islets from the surrounding acinar tissue, as 
reported by others (Ichii and Ricordi, 2009). 
 
 Body mass index (BMI) - Organs referred generally came from donors with a 
higher (>25) BMI. Studies have shown that such donors yield a higher number 
of viable islets (Sakuma et al., 2008, Ponte et al., 2007b, Ichii and Ricordi, 
2009). 
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 Cold ischaemia time (CIT) - Organs were transported by road from the 
retrieval centre (or the transplanting centre which had subsequently rejected 
the organ for clinical use) to our islet isolation laboratory which would often 
prolong the cold ischaemia time. Routinely we would seek to process organs 
with a CIT of less than 12 hours. Prolonged CIT adversely affects islet yield and 
purity (Shapiro et al., 2006). 
 
 Brain-death versus non-heart-beating donor- Most organs referred were 
from brain-dead donors. The degree of warm ischaemia would determine 
whether we accept organs from non heart beating donors which happened in 
exceptional circumstances. Such organs have been shown to yield viable islets 
(Zhao et al., 2007). 
 
 
 Time in ITU- Long periods in intensive care negatively impact islet isolation 
usually giving a poor yield. In this study only pancreata from donors who had 
spent less than 3 days in ITU were accepted.  
 
 Degree of fatty infiltration- Moderately fatty pancreata are associated with a 
higher islet yield (Ponte et al., 2007b) although longer digestion periods may 
be required. 
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 Degree of fibrosis – Highly fibrotic organs resist enzymatic digestion and 
produce a low yield. Severely fibrotic glands were therefore excluded from 
this study. 
 
2.2.2. Pancreas digestion and islet purification  
A favourable ethical opinion was obtained for use of human pancreatic tissue for research 
prior to the start of this study (LREC Q5/2801/47 – Coventry and Warwickshire Ethics 
Committee). In all instances the organs were delivered in a temperature controlled box, on 
ice and double bagged. Prior to processing, the pancreas was examined for an intact capsule 
(required for adequate perfusion and distension of the gland with Liberase) and, if attached, 
the duodenum and spleen were removed. An assessment was carried out to determine the 
degree of fibrosis in the gland (by palpation) and the extent of fat infiltration (by eye) and if 
these were found to be of an appropriate level a decision was made to proceed with islet 
isolation.  
 
The pancreas was transferred to a Class II microbiological safety cabinet. Overlying fat was 
removed along with a small section of the pancreas head in order to clearly expose the 
pancreatic duct. The sections removed from the head were processed for later histological 
and microbiological analysis.  Once all extraneous tissue was removed the pancreas was 
weighed and the duct cannulated. Ductal infusion of a collagenase blend (Liberase – 
3.5mg/ml – Roche Diagnostics Ltd, West Sussex, UK) was then performed injecting a total of 
60ml of enzyme solution into the gland, thus causing distension. The degree of distension 
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was noted. The gland was then placed whole into a 1L glass beaker containing a large 
magnetic flea and 200-250ml of Hanks Balanced Salt Solution (HBSS) was added (sufficient to 
cover the pancreas). The beaker was sealed with parafilm and transferred to a water bath 
where the temperature of the organ and the enzyme solution was raised to 37⁰C. Once the 
required temperature was achieved, the beaker (with contents), was placed in a stirrer oven 
at 37⁰C, thus enabling the liberase to commence enzymatic digestion in combination with 
continuous mechanical agitation. Every 5-10mins a sample of the digesting material was 
collected using a pastette and examined for evidence of liberated islets by staining with 
dithizone (Diphenylthiocarbazone – DTZ, Sigma-Aldrich UK.co.Ltd. – 0.75g/ml – see below 
for further details). If necessary the pancreas was divided into 3-4 pieces during the 
digestion phase to assist islet liberation. On evidence of islet cleavage (i.e. observation of 
islets completely dissociated from surrounding exocrine tissue - usually after 25-30 mins), 
the beaker containing the digested pancreas was returned to the cabinet, and the enzymatic 
reaction stopped by addition of 0.5L of ice cold HBSS supplemented with 0.5% bovine serum 
albumin (BSA, Sigma-Aldrich).   
 
The pancreatic digest was divided equally between 4-6 large conical centrifuge tubes 
(250ml) and centrifuged at 400g for 5 mins and the supernatant discarded. The resulting 
pellets were re-suspended in HBSS + 0.5% BSA (each pellet in 50 ml), and any remaining 
large tissue fragments were removed by passing the digest through a 500mmesh. The 
digest was re-centrifuged at 400g for 5 mins, the supernatant decanted and the pancreatic 
digest re-suspended in 50ml of University of Wisconsin (UW) solution which is an organ 
preservation solution used clinically for the preservation of abdominal organs destined for 
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transplantation, and incubated on ice for 30 mins to allow the islets to de-granulate. The 
digest was then harvested by centrifugation at 300g for 5 mins, the UW solution discarded 
and the total volume of digested material calculated.  
 
For islet purification, Ficoll gradient columns were prepared using Histopaque-1077 (Sigma-
Aldrich) diluted in HBSS+0.5% BSA and the pancreatic digest thoroughly mixed into the 
gradient, ensuring homogeneity.  The gradient:digest mixture was then divided into 50ml 
conical centrifuge tubes (13mls/tube) and “capped” with 5mls of HBSS prior to 
centrifugation at 800g for 5 mins (without brake). Following centrifugation the heavier 
exocrine material formed a pellet while the islets formed a compact layer at the interface 
between the Histopaque and HBSS. A plastic pastette was used to gently aspirate the islets 
from the interface and transferred to a 50ml centrifuge tube. The islets were washed with 
HBSS+0.5% BSA and centrifuged at 300g for 5 mins.  The supernatant was discarded and the 
islet pellets re-suspended in Medium-199 supplemented with 10% foetal bovine serum 
(FBS), 100U/ml penicillin, 100g/ml streptomycin and 10g/ml of amphotericin B.  
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2.2.3. Method for assessment of islet purity, viability, counting and standardisation to islet 
equivalents (IEQ)  
Isolated human islets were stained with DTZ to assist identification and counting. Dithizone 
is traditionally used as a trace for heavy metals as it readily complexes with mercury and 
lead. In islets, dithizone forms a stable complex with zinc ions resulting in the formation of a 
red colour reaction within the insulin containing islets (Latif et al., 1988). Contaminating 
exocrine tissue (non-zinc containing) is therefore readily distinguished from the islets 
enabling subjective analysis of islet purity. 
 
To quantify -cell mass a 10-50l sample of DTZ stained islets was placed in a 24-well tissue 
culture plate the base of which was etched with gridlines to assist orientation and counting.  
Using an inverted microscope equipped with a 1cm2 counting grid (in the eyepiece) all of the 
islets in the sample were counted and sized (100-150 islets per 50l sample). This counting 
procedure was performed in triplicate and the mean values used to calculate islet 
equivalents (IEQ), where each IEQ represents a “standard” islet with a diameter size of 
150m (Ricordi et al., 1990). The structural viability of the isolated islets was assessed by 
Trypan Blue (dye) score, using an adaptation of the technique described by Goto et al (Goto 
et al., 2009). In brief, 50l of islet suspension was diluted in an equal volume of Trypan Blue 
solution (0.4%- Sigma-Aldrich). Following a brief period (3-5 mins) of equilibration the islet 
suspension was viewed under an inverted microscope and examined for evidence of dye 
uptake. Those islets with good structural integrity (i.e. intact membranes) successfully 
excluded the dye whilst damaged cells showed cytoplasmic (blue) staining characteristic of 
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non-viable cells. As islets are multi-cellular structures it was necessary to score the degree of 
dye uptake on a scale of 0 to 3; islets showing no evidence of staining were awarded the 
highest score, heavily stained islets received a score of 0, intermediate scores were assigned 
to islets with only a few cells (between 1 and 5, mainly on the periphery) staining positive for 
the dye. Up to 30 islets were thus sampled and scored; the percentage viability was 
calculated by dividing the aggregate score by the maximum (i.e.90).  
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2.2.4. Islet culture  
Once counted the islet suspension was adjusted to a density of 500-750 IEQ/ml and seeded 
into 90mm untreated culture plates (NHS Logistics, Alfreton) with Medium -199 
supplemented with 10% foetal calf serum (FCS), 100U/ml penicillin, 100g/ml streptomycin 
and 10g/ml amphotericin B. Islets were cultured for 24 hours at 30°C in a humidified 
atmosphere of 95%O2/5% CO2 to allow recovery and acclimatisation prior to functional 
assessment as described below. 
 
2.2.5. Functional Assessment 
Islet functional viability was determined by assessing glucose-stimulated insulin secretion 
(GSIS) 24 hours post-isolation. Static challenge studies were performed as follows:  
Approximately 1000 IEQ were aspirated from the culture dish using a sterile pastette, placed 
into a 15ml conical tube and centrifuged at 400g for 3 mins.  The supernatant was discarded 
and the resultant pellet re-suspended in a 2ml volume of 1.67mM glucose solution made up 
in HBSS+0.2%BSA (basal glucose). Islets were then placed in a water bath at 37⁰C for 1 hour 
(pre-incubation period). During this hour, an islet count as described above was performed 
to ascertain the extent of -cell loss as a consequence of overnight culture.  If necessary the 
islet suspension was readjusted (by the addition of the 1.67mM solution) to a density of 
400IEQ/ml and 50l aliquots (equivalent to 20 IEQ) and transferred to 12mm x 75mm 
polypropylene tubes (NHS Logistics, Alfreton, UK). A total of 18 tubes were thus prepared, to 
which 2ml of the appropriate secretagogue, diluted in HBSS+0.2% BSA, was added as 
follows: 6 tubes received 1.67mM glucose solution to assess basal insulin secretion.  To a 
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further 6 tubes a 16.7mM solution of glucose was added to determine stimulated insulin 
secretion. The remaining tubes received 2ml of 16.7mM glucose supplemented with 10mM 
theophylline; a potentiator of insulin secretion. The racked tubes were sealed with parafilm 
and placed into the water bath at 37⁰C for 1 hour to allow insulin secretion (incubation 
period). Following incubation the tubes were gently vortexed and then centrifuged at 400g 
for 5 mins. The resultant supernatant was harvested for analysis of insulin content using an 
enzyme-linked immunosorbent assay (ELISA; Mercodia, Diagenics UK), according to the 
manufacturer’s instructions. Assessment of glucose-induced insulin secretion is a standard 
method for estimating the functional viability of islets in the early post-isolation period and 
is presented as the stimulation index (S.I; fold increase in insulin release in response to a 
known secretagogue compared to basal secretion). 
 
2.2.6. Statistical analysis 
Statistical differences in response to insulin secretagogues were assessed by one way 
analysis of variance (ANOVA) using insulin secretion under basal conditions as the control. In 
all comparisons a p value of <0.05 was considered to be statistically significant.  Statistical 
analysis was performed using SigmaStat software version 3.5 (Systat Software Inc, Chicago, 
USA). 
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2.3. Results 
A total of seven human pancreata (five female and 2 male donors with a mean age of 
47.14±3.35 years) were procured and successfully processed to obtain the islets used in the 
present study.  The mean cold ischemia time was 10.04±1.25 hours. An average of 70g of 
pancreatic tissue was processed yielding a mean of approx 111,000 IEQ post-purification 
(Table 2). In all instances sufficient numbers of viable islets were isolated for research 
purposes. 
  
2.3.1. Morphological characteristics of isolated islet preparation 
The human islet isolation protocol employed in the present study resulted in the harvest of 
structurally intact islets which were well cleaved from the surrounding exocrine tissue, as 
previously reported (Murray et al., 2009, Murray et al., 2005) (Fig.1).  The purity of the islet 
suspension following Ficoll gradient -assisted separation ranged from 70-85%, with islets 
mostly sized between 100-500m. Trypan Blue exclusion served as an indicator of preserved 
islet structural integrity. 
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Figure 1. Human pancreatic islets visualised by dithizone staining (red cells) observed following pancreatic digestion (A) and after Ficoll gradient 
assisted centrifugation (B). Scale bar = 100m 
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 Table 2 - Donor characteristics and islet isolation outcome for the pancreata used in this study 
 
 
 
 
 
 
Abbreviations; CIT = cold ischemia time, IEQ = islet equivalents 
 
 
 
 
 
 
 
 
 
 
 
 
 
Donor code Age (years) Gender(M/F) Organ descrip. CIT Weight used (g) Purity % Viability IEQ purified
H4190607 52.00 F fatty/fibrous 15.50 70.00 80 71.6 26000.00
H7241107 43.00 F damaged capsule/fatty 10.00 62.00 75 73.3 66000.00
H8141207 31.00 M damage to head/fatty 6.50 102.00 75 70.0 75000.00
H1160108 54.00 M fatty 10.50 84.00 85 73.3 314000.00
H6160508 42.00 F slight damage to capsule 13.00 56.00 70 66.7 103000.00
H7150808 53.00 F damage to head/fatty 7.75 64.00 80 73.3 70000.00
H1240109 55.00 F damage to head 7.00 60.00 65 73.3 125000.00
n 7.00 7.00 7.00 7.00 7.00 7.00
mean 47.14 10.04 71.14 75.71 71.64 111285.71
s.e.m. 3.35 1.25 6.19 2.54 0.95 35755.60
55 
 
2.3.2. Functional Assessment 
Insulin secretory function 24 hours post-isolation 
 In the present study isolated islets gave a robust response to high (16.7mM) glucose which 
was consistently increased (S.I. 2.63±0.21) when compared with basal release. Stimulated 
insulin release was further enhanced by the presence of 10mM theophylline achieving an S.I. 
of 3.67±0.34 (Fig.2.).  
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Figure 2. Insulin secretion from isolated human islets in response to nutrient stimulation during static 
challenge experiments performed 24 h post isolation. Islets were maintained under conventional 
static culture conditions prior to assessment of insulin secretory function. Insulin release was 
measured in response to 1.67 mmol/l glucose (basal release), 16.7 mmol/l glucose and 16.7 mmol/l 
glucose plus 10mmol/l theophylline. Results are expressed as the mean ± SEM fold increase in insulin 
release in response to nutrient stimulation relative to release under basal conditions (stimulation 
index S.I.). n=7 independent islet preparations. The absolute mean value for insulin secretion under 
basal conditions was 86.5±17.2 μUml-1 [20 islets]–1 h–1. * p<0.05 vs. basal conditions. (One way 
analysis of variance) 
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2.4. Discussion 
The aim of the present chapter was to outline the process of procuring human pancreatic 
tissue for research and the subsequent isolation of islets by use of an in-house manual 
separation method.  
 
Clinical islet transplant programmes require standardisation of islet isolation in order to 
conform to strict regulatory guidelines for the manufacture of tissue for transplant purposes. 
The semi-automated method of islet retrieval is amenable to validation with well-defined 
standard operating procedures which may be readily adopted by multiple transplant centres 
involved in clinical trials, ensuring that outcomes may be directly compared (Linetsky and 
Ricordi, 2008). The trade-off arises from the resource-rich and labour-intensive nature of the 
process, with the costs involved making islet isolation prohibitive to all but a few centres 
across the UK, and indeed worldwide (Paget et al., 2007).  
 
Whilst human islets used for research purposes are required to be of a similarly high 
standard the method of islet procurement may differ in terms of the processes employed. In 
contrast to the semi-automated-method where the procedures must be rigidly adhered to, 
the manual method of islet retrieval may be subject to adaptation with changes made to the 
protocol depending on the characteristics of the pancreas being processed. The ability to 
make modifications during the procedure increases the likelihood of successful islet 
isolation, despite the frequent use of marginal (sub-optimal) organs. This ensures optimum 
use of the scarce resource of human pancreatic tissue for islet procurement. 
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In this study the use of a manual method of islet isolation was demonstrated to be an 
effective means of obtaining human islets of suitable quality for research. The technique 
may be readily mastered, with appropriate training, by researchers new to the field. The cost 
of isolation is affordable, conducted by two personnel with fewer consumable resources 
expended and no specialised equipment required in comparison to the semi-automated 
process. Successful isolations were achieved with most organs procured and the yields 
obtained were of an appropriate level (ranging from 25,000-300,000 IEQ per pancreas) for 
the planned experiments.  
 
The pancreata obtained through NHS Blood and Transplant had been declined for use in 
whole organ or islet transplantation. In certain instances this may have been due to 
anatomical incompatibility with the intended recipient or due to clinical service limitations. 
However, on most occasions the organs were deemed unsuitable due to the period of cold 
ischaemia, certain characteristic of the donor (age, BMI, medical history) or due to physical 
damage to the organ. The manual method of islet isolation can be adapted to address these 
shortcomings. For instance, islets from a donor with a high BMI may have fat infiltration 
which would make it unsuitable for islet isolation using the semi-automated method, due to 
the extended period of enzymatic digestion which is required. In the clinical isolation 
process, increasing the digestion phase of the process is problematic and often leads to over 
digestion of the preparation and subsequent islet fragmentation. However, using the manual 
technique, the process of digestion is placed under greater surveillance with frequent 
sampling of the digest (as frequently as every 5 mins) ensuring that islets are liberated 
without risk of excessive digestion. Additionally, use of a discontinuous gradient (as opposed 
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to the COBE 2991) allows greater control of the purification process and conducting it at 
room temperature with less -cell toxic gradients (McCall et al., 2011) provides the 
opportunity to “rescue” poorly fractionated preparations and attempt further separation. As 
a result it was possible to achieve purity of up to 70% in the batches of islets used in this 
study; dithizone staining provided subjective evidence that that there was minimal exocrine 
contamination and enabling us to exclude any compounding effects arising from the 
presence of non-islet cellular components.  
 
It has been argued that the use of manual methods of islet isolation increases the risk of 
bacterial and viral infection (Goto et al., 2004). However, in the present study all islet 
preparations were subject to microbiological analysis (performed by our Trust 
microbiologists) and were found to be free of contaminating pathogens. The additional steps 
involved in isolation are also thought to equate to a loss of morphological or functional 
viability (Gurol et al., 2004). However, in this study, morphological analysis confirmed the 
structural integrity of the cells. Furthermore, the results of the glucose challenge test 
demonstrated the functional viability of the islets, notably their appropriate response to 
nutrient stimulation as observed 24 hours after isolation.  In clinical islet transplantation the 
stimulation index is used, in part, to determine whether a batch of islets meets the criteria 
for transplantation (D'Aleo et al., 2010). In most instances islet preparations with an S.I. 
between 2.5 and 4.0 are transplanted although there is no clear correlation between pre-
transplant S.I. and long-term graft performance (Ryan et al., 2004). This, coupled with the 
purity,  suggests that the islets obtained would have been suitable for clinical use (Linetsky 
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and Ricordi, 2008) and were therefore an appropriate model for use in subsequent studies 
to design low immunogenic tissue constructs for use in  islet transplantation. 
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CHAPTER 3: HUMAN AMNIOTIC EPITHELIAL CELLS: 
ISOLATION, MORPHOLOGICAL AND FUNCTIONAL 
ASSESSMENT 
 
 
3.1. Introduction-Amnion-derived cells as candidates for transplantation therapies 
During gestation the developing foetus is surrounded by amniotic fluid, enclosed in a sac 
lined by the amniochorionic membrane (Fig.3.). The innermost layer is composed of amniotic 
epithelial cells (AEC), resting on a basement membrane and underlying avascular stromal 
cells which collectively form the amniotic membrane (AM) (Hoyes, 1975). The amniotic 
component of the foetal sac originates from the epiblast of the inner cell mass which 
contrasts with the origin of the chorion, derived from extra-embryonic tissues (Benirschke 
and Kaufmann, 2000). 
 
The placenta gives rise to a number of distinct cell populations which have recently become 
the subject of considerable interest in the fields of cell and tissue transplantation and 
regenerative medicine (Parolini and Caruso, 2011, Parolini et al., 2008).  Of note, the stem- 
and progenitor-like characteristics of these cells, coupled with their relative immune-
inertness makes them strong candidates in the search for surrogates for use in cell 
replacement therapy in a variety of clinical situations. The critical role played by the placenta 
during pregnancy is understood to involve maintenance of feto-maternal tolerance, 
preventing the partially allogeneic foetus from being rejected. As a consequence, the 
placenta and its associated membranes are endowed with certain characteristics pertinent 
to the modulation of the surrounding immune micro-environment. Of note, in extensive 
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studies the following human placental derived cell types have been shown to possess 
immuno-modulatory potential with importance for the inhibition of inflammatory and/or 
immune events. 
i. chorionic trophoblastic cells (CTC) – isolated from the chorionic trophoblast of term 
placenta 
ii. chorionic mesenchymal stromal cells (CMSC) – obtained from the mesenchymal layer 
of the chorionic membrane 
iii. amniotic mesenchymal stromal cells (AMSC) – derived from the mesenchymal layer 
of the amniotic membrane  
iv. Amniotic epithelial cells (AEC) – sourced in large quantities from the epithelium of 
the amniotic membrane 
 
For the purpose of the present study this summary will focus on the cells derived from the 
human amniotic membrane; i.e. amniotic epithelial cells whilst the others are 
comprehensively reviewed elsewhere (Parolini and Caruso, 2011).   
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Figure 3. Illustration of the architecture of the human placenta and amniotic membranes 
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3.1.1. Clinical use of human amniotic membrane (AM)  
The low-antigenicity and marked anti-inflammatory properties of human AM underlies its 
importance in reconstructive and transplant medicine. Its’ most acknowledged use is in 
ophthalmic surgery, where using AM as a basement membrane substitute or as a temporary 
graft has become commonplace. AM has been shown to reduce inflammation and scarring, 
prevent angiogenesis and fibrosis and is thought to be the source of certain growth factors 
which encourage the re-epithelisation of the surface of the eye (Meller et al., 2011). Despite 
the absence of controlled randomised clinical data directly supporting the role of AM 
transplantation in ophthalmic surgery, the results of numerous case studies strongly suggest 
that it serves as an effective approach to corneal and conjunctival reconstruction and has 
been successfully applied to the treatment of burns (Meller et al., 2000), acute Stevens-
Johnson Syndrome (Gregory, 2011), intractable corneal ulcers (Nubile et al., 2011) and 
persistent epithelial defects (Seitz et al., 2009).  
 
In addition to its role in ophthalmic surgery AM has also been used in the management of 
ulcers refractory to other treatments, and in venous leg ulcers AM grafts were shown to 
encourage re-epithelisation from the edge of the wound inwards with a concomitant 
reduction in fibrosis and associated pain (Mermet et al., 2007). The treatment of paediatric 
burns using human AM as a temporary graft or for skin graft fixation has also been explored 
clinically with promising results (Sheridan and Moreno, 2001, Mohammadi and Johari, 2010).    
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3.1.2. Clinical potential of human amniotic epithelial cells 
The innate anti-inflammatory characteristics of AM have been attributed, at least in part, to 
the cells lining the membrane surface, the amniotic epithelial cells (AEC) which, when 
isolated, have been shown to exhibit immunomodulatory potential.  In vitro studies 
demonstrate the ability of human AEC to suppress T-cell activation in both mixed 
lymphocyte and mitogen-induced proliferation assays (Wolbank et al., 2007, Li et al., 2005) 
and AEC are amenable to both allogeneic and xenogeneic engraftment in immune-
competent recipients (Akle et al., 1981, Kong et al., 2008, Kubo et al., 2001, Sankar and 
Muthusamy, 2003).  Furthermore, the expression of several mediators of localised immune 
suppression including HLA-G, Fas ligand and TGF have been characterised in isolated AEC or 
culture supernatant (Li et al., 2005, Harirah et al., 2002, Hammer et al., 1997, Kubo et al., 
2001, Lefebvre et al., 2000). Such immuno-mediators have the capacity to counteract the 
potentially harmful actions of immune cells; evidence suggests that AEC may be capable of 
creating a microenvironment conducive to sustained allogeneic graft survival (Wolbank et 
al., 2007, Li et al., 2005, Bailo et al., 2004, Kong et al., 2008, Sankar and Muthusamy, 2003).   
 
Coupled with their relative immune-inertness, AEC also express a variety of stem cell 
markers indicating multi-lineage differentiation potential. Indeed, under defined culture 
conditions human AEC have the capacity to differentiate into cells from all three germ layers, 
giving rise to bone, fat, liver, pancreas and neural cells (Murphy et al., 2010). As such, in 
experimental models, human AEC have been shown to be beneficial in the treatment of 
Parkinson’s disease, stroke, spinal cord injury, DM, peripheral vascular disease, pulmonary 
and liver fibrosis (Parolini and Caruso, 2011). There is limited evidence that differentiated 
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AEC are able to directly participate in tissue regeneration in vivo (Okawa et al., 2001). 
However, the beneficial AEC-mediated effects observed are largely considered to be due to 
the secretion of bioactive molecules that act on other cells and promote endogenous tissue 
repair through paracrine effects (Parolini and Caruso, 2011).   
 
A substantial body of evidence therefore exists in favour of a role for human AEC in 
regenerative medicine. When compared with stem cells derived from an embryonic source, 
the wide availability and relative lack of ethical constraints associated with procurement of 
this tissue make AEC an ideal candidate for further exploration. 
 
Aims of the Chapter 
 This study aims to provide evidence that AEC may be used as an adjunct to islet cell 
transplantation, offering vital trophic support, whilst simultaneously protecting the islet 
graft from immune assault. In the following sections we describe the methods of isolation 
and subsequent characterisation of the AEC used in the present investigation, including their 
immunomodulatory potential. 
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3.2. Materials and Methods: I: AEC Isolation and morphological characterisation 
 
3.2.1. Donor recruitment and consent 
All studies using human amniotic tissue were performed according to ethically approved 
protocols (LREC: Q5/2801/70- Coventry and Warwickshire Ethics Committee) and with the 
informed consent of the tissue donor. For amniotic membrane procurement, potential 
participants were identified from an elective Caesarean section list. Women undergoing 
normal vaginal delivery were excluded from the study to reduce the risk of microbial 
contamination of the amnion sample. The prospective tissue donors were seen in the pre-
operative clerking clinic 24 hours beforehand and given information about the research 
project. Following discussion of the proposed work, women were invited to take part in the 
study and if appropriate gave informed, written consent prior to delivery. 
 
3.2.2. AM harvest and dissociation 
The amnion was harvested under aseptic conditions in the operating theatres. After the 
placenta had been delivered and inspected by the midwife, the AM was mechanically 
dissociated from the chorion layer. 2-3.5 cm2 pieces were stripped off and washed twice in 
150ml of filter sterilised PBS containing 100U penicillin, 100g streptomycin and 10g 
amphotericin B. The tissue was placed in a sterile pot containing 100ml of filter sterile PBS 
supplemented with 200U penicillin, 200g streptomycin and 20g amphotericin B for 
transport to the laboratory. 
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Figure 4. Human amniotic membrane mechanically separated from the chorion. Samples not 
in direct contact with the placenta were collected for processing. 
 
amnion 
chorion 
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The tissue was transferred to a Class II microbiological safety cabinet and the amnion was 
cut into small pieces to increase its surface area. The AM fragments were placed in a conical 
tube containing HBSS before being centrifuged at 400g for 5 mins (brake set to 5). The 
supernatant was decanted leaving the pelleted amniotic tissue. A 0.25% solution of porcine 
Trypsin (Sigma-Aldrich) was made up in HBSS in a sterile container and placed in a water 
bath to reach a temperature of 37⁰C. Once achieved, 100ml of the trypsin solution was used 
to re-suspend the amnion tissue and both were transferred to a glass beaker equipped with 
a magnetic flea. The beaker was tightly sealed with a layer of parafilm and placed in a stirrer 
oven at 37⁰C for 30 mins.  
 
Following the first digestion period the dissociating tissue was passed through a 500m 
mesh to harvest any detached cells; the tissue retained by the mesh was collected and 
returned to the glass beaker, re-suspended in a fresh 100ml volume of 0.25% trypsin 
solution and placed in the stirrer oven for a further 30 mins incubation period. The collected 
filtrate (Fraction 1) was placed into 50ml conical tubes and centrifuged at 700g for 5 mins 
(brake set on 5). The supernatant was decanted and the cell pellet re-suspended in 2mls 
RPMI 1640 containing 10% FBS, 100U/ml penicillin, 100g/ml streptomycin and 10g/ml of 
amphotericin B.  
 
The above process was repeated until the amniotic epithelium was fully dissociated and the 
resulting, dispersed AEC were collected in a total of 4 separate cell fractions (Fractions 1-4), 
each of which was suspended in 2mls RPMI 1640 medium containing additives as described 
above. In most instances fraction 1 was discarded due to the high number of contaminating 
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red blood cells. Fractions 2-4 were subsequently pooled and plated into T-75 flasks. Each 
flask received 1ml of cell suspension (containing between 1-3 million AEC) and was made up 
to 20ml total volume with RPMI 1640 + additives. The flasks were transferred to an 
incubator for 48 hours at 37 °C in a humidified atmosphere of 95%O2/5% CO2 to allow cell 
attachment. At the first medium change (48-72 hours) 15mls of medium was removed from 
each flask and replaced with 10mls of fresh medium. Thereafter a full medium change 
occurred at 2-3 day intervals. Flasks of dispersed amniotic epithelial cells reached confluence 
at between 7-10 days post isolation. In this study AEC were routinely used at passage 1 and 
at this time the cells were counted and assessed for viability. 
 
3.2.3. Passaging of AEC – assessment of yield and viability 
At confluence AEC cultures were passaged as follows:   
The flasks containing the AEC monolayers were transferred to the hood and the medium was 
gently aspirated using a sterile 10ml pipette. This was immediately replaced with 10mls of 
filter sterilised PBS (Sigma-Aldrich) which was used to rinse the cells. Rinsing was performed 
3 times to ensure all of the FBS-containing culture medium was removed (as this would 
inhibit the subsequent trypsinisation process). 1ml of 0.025% Trypsin-EDTA in PBS (Sigma-
Aldrich) was added to each flask, gently swirling the flask to ensure that the entire 
monolayer was covered by the enzyme. The flasks were then returned to the incubator for 
20mins to assist mild dissociation of the monolayer. The AEC monolayers were viewed under 
an inverted microscope to assess the level of disruption; AEC rolled up and become 
detached from the base of the flask as the trypsin took effect. If necessary, cell detachment 
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was further assisted by gently tapping the flask against the palm of the hand. Once all the 
AEC were free-floating the trypsin reaction was quenched by addition of 10ml of culture 
medium contain 10% FBS. The AEC suspension was harvested into 50ml conical tubes for 
centrifugation at 500g for 3 mins. Each AEC pellet was re-suspended in 1ml of culture RPMI 
1640+ additives, (i.e. 1 ml of culture medium per flask of AEC) and all the pellets were 
pooled for counting and viability assessment.  
 
Samples of AEC (50-100l) were placed in an Eppendorf tube to which an equal volume of 
0.4% Trypan Blue solution was added. Following mixing, a portion of the cell suspension was 
used to fill the lower counting chamber of a haemocytometer – by capillary action. Cells 
occupying the 4 quadrants (composed of 16 squares) of the chamber were counted and the 
mean value used to determine the total cell number in one ml of suspension. From this total 
AEC numbers were calculated. In addition, the non-viable cells (i.e. blue-stained) in each grid 
were counted to give the percentage cell viability. The AEC suspension was adjusted to a 
final density of 1x106/cells per ml for subsequent use or for cryopreservation. 
 
3.2.4. AEC Cryopreservation 
As the ultimate aim of this study was to determine whether human AEC could be applied to 
clinical cell transplantation we sought to determine whether these cells were amenable to 
cryopreservation thus ensuring their ready availability. To this end studies were performed 
to assess AEC function following a period in ultra-low temperature storage. AEC at passage 1 
(P1) were counted as described above and adjusted to a final density of 1x106 cells per ml in 
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RPMI 1640 + additives and 10% dimethyl sulfoxide (DMSO – Sigma-Aldrich, cell culture 
tested). After allowing 5 mins of equilibration the cells were transferred to 1ml cryo-tubes™ 
(Appleton Woods, Birmingham, UK) and placed in a Nalgene® “Mr Frosty” (Fisher Scientific, 
Loughborough, UK). This solvent-assisted cooling chamber permitted controlled, step-wise 
freezing of the AEC cryo-solution to a temperature of - 45°C over a 24 hour period. After this 
the tubes were racked and stored at - 80°C for up to 3 months. 
 
3.2.5. AEC Histological Characterisation 
P1 AEC were counted and adjusted to a final density of 1 x 106cells/ml in supplemented 
RPMI 1640, as previously described. A 24-well culture plate was prepared by placing a pre-
washed and autoclaved 13mm glass coverslip in the base of each well and adding 950l of 
culture medium. 50l of cell suspension was then added, giving a total of 50,000 cells per 
well and the plate was placed at 37 °C in a humidified atmosphere of 95%O2/5% CO2 to 
allow cell attachment. After approximately 72 hours the AEC attached to the glass coverslips 
at which time they were processed for histology as follows: 
Sub -confluent AEC monolayers were fixed with freshly made 4% paraformaldehyde (Sigma –
Aldrich) in PBS for 30 mins at room temperature (RT).  Three 10 mins washes in PBS were 
followed by antigen-retrieval (0.3% Triton-X-100, Sigma- Aldrich) and blocking using either 
10% normal goat serum (NGS) or 10% normal rabbit serum (NRS – both from Vector 
Laboratories Ltd, Peterborough, UK) depending on the species in which the secondary 
antibody was raised.  The AEC monolayers were then incubated with the following primary 
antibodies: anti-human cytokeratin 19 (CK19), anti-human vimentin (Dako UK Ltd, 
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Cambridgeshire, UK– 1:100), anti-human insulin (AbD Serotec, Oxford, UK 1:10) and anti-
human Fas Ligand (FasL, Sigma-Aldrich, 1:50), for 1 hour at RT and at 4°C overnight. 
Secondary antibody (goat anti-mouse IgG-FITC for CK19, vimentin, FasL, goat anti-rabbit IgG- 
TRITC for insulin – Cambridge Biosciences, Cambridge, UK, 1:100) was applied for 3 hours at 
RT.  The coverslips were rinsed and mounted in fluorescence mounting medium (Dako UK 
Ltd) before cell imaging using a Zeiss Axioskop 40 fluorescence microscope equipped with an 
AxioCam MRC colour camera and incorporating Axiovision imaging software (Carl Zeiss, 
Hertfordshire, UK).  Controls involved omission of the relevant primary antibody. 
 
3.2.6. Analysis of cytokine Profile of AEC supernatant and lysate 
Cell supernatants collected from cultured AEC (plated at 50,000cells/ml for 72 hours) and 
cell lysates prepared by mild sonication of cultured AEC were processed by Randox 
Laboratories Ltd. Using BioChip Array Analysis (BAT) a comprehensive panel of 12 cytokines 
relevant to immune modulation were investigated in the AEC samples. In this study the 
Cytokine Array I High Sensitivity assay was used which detects Interleukin (IL)-1 α,IL-1β, IL-
2,IL-4,IL-6, IL-8, IL-10, Epidermal Growth Factor (EGF), Interferon-γ (IFN-γ), Monocyte 
Chemotactic Protein-1 (MCP-1), Tumour Necrosis Factor-α (TNF-α), and Vascular Endothelial 
Growth Factor (VEGF). Due to the combination of highly specific antibodies and advanced 
chemistries the array enables all 12 cytokines and growth factors to be detected 
simultaneously in a single sample. The limit of sensitivity for each analyte is presented in 
table 3.  Each sample was measured in duplicate and 2 samples from each group 
(supernatant or lysate) were provided for analysis. 
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3.3. Material and Methods II: Assessment of Immunomodulatory potential 
3.3.1. Isolation of peripheral blood mononuclear cells (PBMC) 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats obtained from 
healthy volunteers through the National Blood Service (NBS, Birmingham, UK) with local 
research ethics approval and with the consent of the donor. In all instances the buffy coats 
came from regular blood donors who were screened for pathogens and who were free of 
any illness which might adversely affect lymphocyte reactivity.  To isolate the PMBC, buffy 
coats were collected into 150 ml sterile pots and diluted in an equal volume of HBSS. This 
was carefully layered onto 12ml of density gradient adjusted to 1077g/ml (Histopaque®-
1077 - Sigma-Aldrich), centrifuged at 700g for 30 mins (with no brake), and the resulting 
leucocyte layer harvested from the interface using a sterile pastette. The isolated PBMC 
were washed three times in HBSS, centrifuged at 500g for 10 mins, re-suspended in RPMI 
1640 (supplemented as described above). The separated PBMC were counted using 
haemocytometer and viability was assessed using trypan blue exclusion. The cells were then 
cultured in uncoated plastic petri dishes at 37°C, 5%CO2, 95%O2 overnight. The PBMC 
cultures were incubated overnight, half of them in the presence of the plant mitogen 
phytohaemagglutinin (PHA, Sigma-Aldrich, 5g/ml), for 24 hours prior to use in proliferation 
assays. 
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3.3.2. AEC vs. PBMC – Proliferation Assay 
AEC at P1 were prepared as described in section 3.2.3 above. Once adjusted to a final 
volume of 1x106cells/ml in supplemented RPMI 1640, aliquots of the AEC suspension were 
added to the appropriate wells of a 24-well plate. In preliminary studies a dose response 
curve was performed plating AEC at 5,000, 50,000 and 500,000 AEC per well. Each well was 
supplemented with medium up to a total volume of 1ml and the plates placed at 37°C, 
5%CO2, 95%O2 for 72 hours to permit cell anchorage.  Additionally, in selected experiments 
cryopreserved AEC were rapidly thawed, rinsed in PBS and seeded as described above for 
the fresh AEC prior to their use in PBMC assays as follows: AEC seeded plates were 
processed by repeated washing in filter sterile PBS to ensure all unattached cells/cellular 
debris was removed from the wells.  Resting or PHA-activated PBMC were added at a density 
of 50,000 cells/well either alone which served as a control or to wells pre-seeded with 
50,000 firmly anchored AEC prior to co-incubation at 37°C, 5%CO2, 95%O2.   Activated PBMC 
continued to be cultured in the presence of 5g/ml PHA throughout the assay period. After 
72 hours the PBMC were harvested, washed and assayed for intracellular ATP content as 
described in section 3.3.4 (below). 
 
3.3.3. AEC conditioned medium (CM) vs. PBMC 
In additional selected experiments P1 AEC were re-plated into T-75 flasks at a density of 
2x105cells/ml (equivalent to 3x106cells per flask) in 15mls of supplemented RPMI 1640 
medium. The flasks were left for 72 hours without a medium change to allow concentration 
of putative soluble factors released by the AEC. The resulting AEC-conditioned medium (CM) 
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was harvested and centrifuged at 1300g to ensure removal of all cells/cellular debris prior to 
use in PBMC proliferation assays. 0.5ml of CM was dispensed to the appropriate wells of a 
24-well plate and 5 x 104 resting or PHA activated PBMC were added; adjusting the total 
volume to 1.0ml using standard RPMI medium. Plates were incubated at 37°C, 5%CO2, 
95%O2.   After 72 hours the PBMC were harvested, rinsed and processed as described in 
section 3.3.4 (below). 
 
3.3.4. Quantification of PBMC proliferation - luminescent detection of intracellular ATP 
After 72 hours the harvested PBMC were solubilised using cell lysis reagent (Vialight – Lonza 
Ltd, Wokingham, UK) and analysed for ATP content using a commercial chemiluminescence 
assay (Lonza Ltd) according to the manufacturer’s instructions.  Concentration of ATP per 
well, measured as relative light units (RLU) is directly proportional to cell number and thus 
indicative of the proliferative activity of PBMC in culture (Sottong et al., 2000).  Results were 
expressed as the percentage increase in relative cell number compared to the control viz. 
resting PBMC incubated in the absence of AEC.  
 
3.3.5. Statistical analysis 
Significant differences in PBMC proliferation in response to co-culture with AECs was 
determined using Mann-Whitney U (by Rank) and Tukey’s multiple comparison tests, with 
the response of resting PBMC serving as the control. In all comparisons a p value of <0.05 
was considered to be statistically significant.  Statistical analysis was performed using 
SigmaStat software version 3.5 (Systat Software Inc, Chicago, USA). 
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3.4. Results I 
3.4.1. Morphological characteristics of isolated AEC 
Human amniotic epithelial cells when isolated from the membrane and held in suspension 
culture readily adopted a spherical morphology forming an apparently homogeneous 
population (Fig.5.A). Once plated at high density in T75 flasks AEC readily attached and 
flattened to form a monolayer (Fig.5.B), the vast majority of these cells staining positive for 
the epithelial cell marker cytokeratin 19 (Fig.5.C).  Additionally, a discreet sub-population of 
cells stained positive for the intermediate filament marker vimentin (Fig.5.D). 
 
3.4.2. Cytokine Analysis –multiplex immunoassay 
AEC supernatants collected after 72 hours of culture as described in section 3.2.6., and cell 
lysates prepared from AEC monocultures were processed by Randox Laboratories Ltd using a 
cytokine array multiplex immunoassay. 
Several cytokines relevant to immune-modulation were detected either in AEC cell 
supernatant, lysate or both, as presented in Table 3. Despite using AEC at the same density 
as that employed in the proliferation assays the concentration of cytokines detected were, in 
many cases, below the level of sensitivity for the immunoassay. 
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Figure 5. Human amniotic epithelial cells (AEC) viewed by light microscopy immediately following 
isolation (A),  viewed first under phase contrast (B) and using fluorescence immunocytochemistry for 
the localisation of the epithelial cell marker cytokeratin 19 (CK19) ( C) and the intermediate filament 
protein vimentin (D). A  FITC-conjugated secondary antibody was used for visualisation. Vimentin 
expression by AEC maintained in monolayer culture differs from that of CK19 which is a cytoskeletal 
protein marker and is distributed throughout the cytoplasm.  Most epithelial cell types co-express 
vimentin. For A original magnification x40, B,C,D  Scale bar = 100m. 
A B 
 
C D 
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Table 3: Cytokine analysis 
 
 
 
 
 
 
                       ND = not detected
 
IL2 
(pg/ml) 
IL4 
(pg/ml) 
IL6 
(pg/ml) 
IL8 
(pg/ml) 
IL10 
(pg/ml) 
INF
(pg/ml) 
TNF
(pg/ml) 
IL1
(pg/ml) 
IL1
(pg/ml) 
MCP1 
(pg/ml) 
VEGF 
(pg/ml) 
AEC 
Supernatant 
5.69 3.21 6.43 2.45 ND ND ND ND 0.76 24.76 60.34 
AEC Lysate 5.24 4.24 ND ND 1.2 ND ND 1.07 0.67 26.81 ND 
Limits of 
Detection 
4.8 6.6 1.2 4.9 1.8 3.5 4.4 0.8 1.6 13.2 14.6 
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3.4.3. Results II – Immunomodulatory Potential of isolated AEC and AEC-conditioned 
medium 
 
PBMC proliferation was evident following exposure to the plant-derived mitogen – 
phytohaemagglutinin - 5g/ml (PHA) as demonstrated by a robust (20-fold) increase in 
intracellular ATP concentration as measured by chemiluminescence detection. By contrast, 
despite the fact that the two cell populations are derived from different donors and are 
therefore allogeneic, PBMC grown in the presence of varying numbers of human AEC failed 
to proliferate to a significant degree. At the highest concentrations of AEC (i.e. 50,000 and 
500,000) there was a slight increase in PBMC numbers but this did not reach statistical 
significance and was small in comparison to the magnitude of response seen to the non-
specific mitogen. PHA-mediated PBMC stimulation was significantly reduced by their co-
culture with AEC. In the dose response experiment AEC-induced inhibition of PBMC 
proliferation was evident at an AEC:PBMC ratio of 1:10 (Fig.6) demonstrating a 60% 
inhibition in cell numbers compared to the control viz. PBMC expansion in the absence of 
AEC. Increasing numbers of AEC inhibited PBMC proliferation by a similar magnitude.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 6. Modulation of peripheral blood mononuclear cell (PBMC) proliferation by co-incubation with varying 
numbers of human amniotic epithelial cells (AEC): AEC were plated at 5,000 (5K), 50,000 (50K) or 500,000 
(500K) cells/ml into 24-well plates and allowed to firmly attach for up to 72 hours. PBMC were then added and 
incubated either in the absence (      ) of presence (      ) of the plant mitogen phytohaemagglutinin (5g/ml) for 
a further 72 hours. The rate of PBMC proliferation following this period was measured using an ATP 
chemiluminescence assay. Data shows the percentage increase above control (resting PBMC) from 3 individual 
AEC preps and represents the typical observation. * p < 0.05, ** p < 0.01 PHA induced increase in PBMC 
numbers as compared to resting control.  † p< 0.01 inhibition of PHA-activated PBMC proliferation in the 
presence vs. absence of AEC.  (Mann-Whitney U (by Rank) and Tukey’s multiple comparison tests) 
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As this study seeks to provide evidence to justify clinical application of AEC in cell 
transplantation therapy it was important to ascertain whether these cells were amenable to 
cryopreservation. To this end in a sub-set of experiments AEC which had been frozen for 
between 1 and 3 months were used to determine their immunomodulatory capacity in 
relation to PBMC. When compared to fresh AEC, cryopreserved AEC elicited a mild 
stimulation of PBMC on co-culture (Fig.7). However this response was small in comparison to 
their response to PHA. A similar magnitude of inhibition (55%) of PHA-mediated proliferation 
was observed when PBMC were co-incubated with either fresh or cryopreserved AEC.  
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Figure 7. Modulation of peripheral blood mononuclear cell (PBMC) proliferation by fresh (A) and cryopreserved human amniotic epithelial 
cells (AEC) (B). Resting (    ) or PHA-activated (    ) human PBMC were maintained in 24-well plates either alone, or in the presence of an 
equal number of human amniotic epithelial cells for a period of 72 hours.  The rate of PBMC proliferation following this period was 
measured using an ATP chemiluminescence assay. Data shows the percentage increase above control (resting PBMC) from 6 individual 
AEC preps and represents the typical observation in fresh and cryopreserved AEC. * p < 0.05, ** p < 0.01 compared to control.  † p< 0.01 
for PHA-activated PBMC proliferation in the presence or absence of AEC. (Mann-Whitney U (by Rank) and Tukey’s multiple comparison 
tests) 
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In a sub-set of experiments the effect of AEC- conditioned medium on PBMC proliferation 
was also determined.  In our study AEC- conditioned medium had comparable 
immunosuppressive activity on PHA-activated PBMC as the AEC inhibiting proliferation by up 
to 60% (Fig.8).  
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Figure 8. Modulation of peripheral blood mononuclear cell (PBMC) proliferation during exposure to 
AEC-conditioned medium (CM). Resting (     ) or PHA-activated (      ) human PBMC were maintained in 
24-well plates either alone or in the presence of 0.5mls of AEC-conditioned medium for a period of 
72 hours.  The rate of PBMC proliferation following this period was measured using an ATP 
chemiluminescence assay. Data shows the percentage increase above control (resting PBMC) from 4 
individual AEC-CM preps and represents the typical observation. * p < 0.05, ** p < 0.01 compared to 
control.  † p< 0.01 for PHA-activated PBMC proliferation in the presence or absence of AEC-
conditioned medium. (Mann-Whitney U (by Rank) and Tukey’s multiple comparison tests) 
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3.4.4. Immunocytochemical analysis of immune mediators 
In an attempt to identify other potential immune modulators underlying the inhibitory 
actions of human AEC, we sought to identify Fas Ligand expressing cells within P1 AEC 
monocultures. The Fas/FasL pathway has been implicated in feto-maternal tolerance and 
has previously been shown to be expressed in foetal membranes (Koenig and Chegini, 2000) 
and amniotic cells (Li et al., 2005). The results of the immunocytochemical investigation 
confirm that a small sub-population of AEC express FasL in culture. Whilst counterstaining 
for cell nuclei was not performed in this study a comparison of the cell populations using 
phase contrast and fluorescence microscopy suggests that approximately 30% of the AEC 
population exhibited cytoplasmic localisation of FasL protein (Fig.9). 
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Figure 9. The images (right) show FasL expressed by AEC .FasL is a soluble membrane bound protein 
expressed by approx. 30% of isolated AEC. Scale Bar = 100m B 
A 
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3.5. Discussion 
The results of this series of studies suggest that AEC are capable of eliciting a suppressive 
effect on peripheral mononuclear cell proliferation, inducing effective inhibition even at a 
ratio of 1:10 for AEC:PBMC. The immunomodulatory capabilities of human amniotic 
membrane have been studied extensively (Hori et al., 2006, Kubo et al., 2001, Trelford et al., 
1975).  Our findings that isolated AEC abrogate mitogen-induced PBMC proliferation confirm 
the results of previously published studies using comparable amnion-derived epithelial cell 
populations (Li et al., 2005, Wolbank et al., 2007). Furthermore, the findings of the 
conditioned medium studies support those of others (Ueta et al., 2002, Hori et al., 2006, Li et 
al., 2005) and, indicate that AEC secrete immunomodulatory factors at concentrations 
sufficient to create a microenvironment of localised immunosuppression. 
 
PBMC numbers did not increase during co-culture with AEC suggesting a lack of allo-
antigenicity. This may relate to the absence of HLA-A, -B, -C or -DR antigens, reported for 
AEC in culture and the lack of MHC Class I and low level expression of MHC Class II in primary 
AEC at low passage (Akle et al., 1981, Adinolfi et al., 1982). In addition, cultured AEC show a 
lack of surface expression of co-stimulatory molecules (CD80, CD86 and CD40) (Pratama et 
al., 2011). Their expression and that of HLA is required for appropriate T-cell activation and 
progression of a full allogeneic response. As such, their absence confers a degree of 
immune-privilege on AEC, as found in the present study, and may have relevance to their 
wider use in clinical transplantation.  
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In addition to being immune inert, AEC elicit a marked decrease in PHA-mediated PBMC 
proliferation during co-culture, suggesting these cells have an immunosuppressive capability. 
This has been reported in other studies which indicate that AEC secrete immunomodulatory 
factors pertinent to the suppression of the innate and adaptive immune responses. 
Characterisation of the mediators involved have been conducted resulting in the 
identification of several soluble factors including TGF, HLA-G, IL-6 and IL-10 (Lefebvre et al., 
2000, Li et al., 2005, Pratama et al., 2011) all of which have the potential to affect localised 
immunosuppression.  The limited cytokine analysis performed in the present study confirms 
the localisation of certain anti-inflammatory cytokines either in the AEC-conditioned 
medium or in AEC cell lysate. However, very low concentrations of cytokines including 
certain pro-inflammatory cytokines, notably IL-2 and IL-8 were also detected. It has been 
suggested that the immunomodulatory properties of certain stem cells including 
mesenchymal stem cells are activated in the presence of pro-inflammatory mediators (e.g. 
TNF1, INF) (Bassi et al., 2011) which act through Toll-like receptors to increase the 
production of immune regulatory factors. Thus, it is possible that a more relevant AEC 
cytokine profile may be determined by measuring the AEC supernatant following exposure 
of the cells to pro-inflammatory molecules. Nevertheless, the anti-inflammatory mediators 
we have detected and which have also been reported by others are known to cause T-cell 
arrest through a number of pathways. TGF- inhibits Th1 proliferation and as a result 
rebalances the Th1/Th2 ratio toward Th2 – anti-inflammatory. In addition TGF- and IL-6 
prevent dendritic cell (DC) maturation and induces T-reg expression, whilst HLA-G-mediates 
inhibition of T-cell proliferation and the suppression of the cytotoxic activity of Natural Killer 
(NK) cells (Bassi et al., 2011). AEC may also secrete or enhance DC secretion of IL-4 and IL-10 
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thus reducing the prominence of Th1 in favour of Th2 cells and creating a more anti-
inflammatory, tolerogenic microenvironment.  
 
Finally, from the results of the limited immunocytochemical analysis it is evident that AEC 
express immune-modulators. Localisation of FasL in a sub-population of AEC indicates the 
potential involvement of the Fas/FasL pathway in the underlying mechanism of T-cell arrest. 
FasL is an immunomodulatory factor associated with naturally occurring T-cell evasion in the 
testis, eye, and brain (Green and Ferguson, 2001). Localisation of FasL within the placenta 
and amnio-chorionic membranes is implicated in maternal tolerance developed to the foetus 
during pregnancy (Kauma et al., 1999, Harirah et al., 2002). In the present study expression 
of FasL in the AEC monocultures raises the possibility that FasL- mediated apoptosis of Fas 
bearing T-cells may also play a role in the absence/loss of T-cell proliferation during 
PBMC/AEC co-culture. Thus, in the context of cell transplantation, AEC are associated with a 
number of factors which have the capacity to directly or indirectly modulate the immune 
system. A number of these mediators could potentially operate in concert to produce a 
microenvironment capable of sustaining allogeneic tissue by diminution of the T-cell 
response.  
 
In terms of their clinical application, the findings of the present study indicate that human 
amniotic membrane represent a source of a readily expandable population of 
immunomodulatory cells which are amenable to cryopreservation without loss of function. 
The tissue is readily available, through elective Caesarean section, and as it is generally 
viewed as clinical waste, it is not subject to significant ethical constraints. The ability of AEC 
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to create localized immunosuppression is supportive of their potential role in creating 
immune-tolerance in allogeneic tissue and cell transplantation with significance for the 
further development of regenerative therapy for the treatment of diabetes and other 
chronic conditions. 
 
In Chapter 4 we detail studies which extrapolate this hypothesis to determine whether the 
inherent immunosuppressive properties of isolated AEC could be manipulated to confer a 
state of immune-privilege onto otherwise immunogenic cell populations.   
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CHAPTER 4:  BIO-ENGINEERING OF ISLET:AEC CONSTRUCTS; 
MORPHOLOGICAL AND FUNCTIONAL CHARACTERISATION 
 
 
4.1. Introduction 
The separation and purification of the endocrine component of the pancreas is imperative to 
successful clinical islet transplantation yet the isolation process, involving both enzymatic 
and mechanical disruption of the human pancreas, negatively influences long-term islet 
viability.  The intact pancreas has a microenvironment which is conducive to islet function; 
appropriate -cell activity being dependent not only on interaction with other endocrine 
cells, (, , pp) but also with the non-endocrine compartment of pancreas and the 
extracellular matrix (ECM) in which islets are embedded (Hopcroft et al., 1985, Ilieva et al., 
1999). Cell-to-cell and cell-to-ECM communication is disrupted during islet isolation leading 
to the elimination of trophic/paracrine support provided by the non-endocrine pancreatic 
cells and also loss of structural viability, resulting in a decline in -cell numbers. This is 
considered to be responsible, at least in part, for the eventual diminution of islet graft 
function in the post-transplantation period.   
 
 It has been suggested that the pre-transplant culture of islets represents a “window of 
opportunity” to perform interventions aimed at rehabilitating “isolation- impaired” islets 
and also to endow them with attributes to enhance their survival in the post-transplant 
setting.  Although not incorporated in the original Edmonton Protocol (Shapiro et al., 2000) 
other participants in the Islet Transplantation Network (ITN) have successfully cultured islets 
prior to implantation allowing time to confirm islet cell viability and sterility and enabling the 
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preparation and pre-treatment of the potential graft recipient with novel 
immunosuppression protocols (Kin et al., 2008, Froud et al., 2005).  
 
 
A number of approaches have been used to enhance islet function in culture. These include 
alteration of temperature and culture media composition (Clayton et al., 2001, Kim et al., 
2005, Brandhorst et al., 2005), culturing on surfaces coated with relevant ECM components 
(Xiaohui et al., 2006), islet encapsulation (Mikos et al., 1994, Beck et al., 2007, Kizilel et al., 
2005), the use of bioreactors (Stepkowski et al., 2006, Rutzky et al., 2002, Murray et al., 
2009, Murray et al., 2005, Tobin et al., 2001) and  co-culture models (Murray et al., 2009, 
Johansson et al., 2008, Johansson et al., 2005, Tian et al., 2005, Park et al., 2010). In the 
present chapter we will outline the findings of studies where the latter two approaches have 
been combined in an attempt to improve -cell function whilst simultaneously altering the 
immune profile of isolated islets.   
 
Previous research in this laboratory has demonstrated the advantage of culturing islets in a 
novel rotational cell culture system (RCCS) based on original bioreactor technology 
developed as part of the National Aeronautics and Space Administration (NASA) space 
program (Paget et al., 2011, Murray et al., 2009, Murray et al., 2005). In an attempt to study 
the effect of microgravity on human cells NASA developed a rotary cell culture chamber, 
known as a Rotating Wall Vessel (RWV) which enables cells and tissue constructs to 
experience low gravity conditions; held by the continuous circular motion of the fluid 
medium. The RWV promotes re- assembling of cells into anatomically appropriate three-
dimensional structures over extended periods of time, forming tissue constructs with 
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relevant functionality (Unsworth and Lelkes, 1998). The technology was made commercially 
available and researchers, including those of this laboratory, have further adapted 
microgravity cell culture to study a wide variety of human cells and tissues under conditions 
appropriate for their long term survival (Navran, 2008).  
 
The Rotational Cell Culture System (RCCS) used in the present investigation incorporates use 
of High Aspect Ratio Vessels (HARV) to simulate low gravity microenvironment where 
continuous cell movement allows optimal oxygenation and nutrient transport. The human 
islets are kept in a semi-buoyant state avoiding contact with the vessel walls thus limiting 
physical damage, central necrosis and fibroblast overgrowth (Murray et al., 2005). 
Furthermore, the minimal shear forces and enhanced cellular contact prevents the cells from 
being exposed to the detrimental effects of mechanical stirring supporting propagation of 
physiologically appropriate cell aggregates (Murray et al., 2005, Murray et al., 2009). Studies 
performed in this laboratory suggest that when maintained within the RCCS human islets 
exhibit preservation of structural integrity and glucose stimulated insulin release over a 10-
day culture period; superior to the results obtained by culturing islets in the conventional 
static culture conditions (CSC) (Murray et al., 2005, Daoud et al., 2010). This time frame 
allows pre-transplant manipulation of islets to enhance function and improve long-term 
graft survival. Further studies indicate significant remodelling of islets under rotational cell 
culture conditions which promotes the transport of nutrients to the islet core, as well as the 
depletion of dendritic cells which serves to reduce islet immunogenicity (Rutzky et al., 2002, 
Stepkowski et al., 2006).  
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Our own and other studies report a positive impact on islet function resulting from the 
experimental co-culture of islets with other relevant cell types. Notably, trophic support to 
islets has been demonstrated by their co-culture with pancreatic ductal epithelial cells 
(Murray et al., 2009), dermal fibroblasts (Jalili et al., 2011) bone marrow-derived 
mesenchymal cells (Duprez et al., 2011), and Sertoli cells (Li et al., 2011, Teng et al., 2005) 
with enhancement of islet function and/or graft survival being reported. It is considered that 
these cell populations interact with islets in a paracrine fashion, releasing trophic factors 
with relevance to -cell survival, proliferation and differentiation including insulin-like 
growth factor (IGF) - I and -II, epidermal  growth factor (EGF), hepatocyte growth factor 
(HGF), transforming growth factor (TGF)-beta and keratinocyte growth factor (KGF)  (Adams 
et al., 1994, Dheen et al., 1997, Robertson et al., 2008, Jiang and Harrison, 2005). 
Additionally, components of the extracellular matrix are vital for appropriate pancreatic 
development and several integrin receptors and their associated ligands including laminin, 
fibronectin and collagen I are expressed by these cell types, notably epithelial cells (Jiang et 
al., 1999, Cirulli et al., 2000, Jiang and Harrison, 2005).    
 
We therefore propose that combining the use of bioreactor technology with tissue-
engineering to modify the function of transplantable therapeutic cells represents a novel 
approach to improving clinical outcomes in islet replacement therapy. It is our hypothesis 
that islet cells may be modified in vitro and adapted under defined culture conditions to 
enhance survival in the post-transplant environment.   
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Aims of the Chapter 
The specific aim of this section of the project was to construct heterotypic cell composite 
grafts with the capacity to: 
 
 provide important  paracrine regulatory and trophic support to native beta-cells by the 
synthesis and release of appropriate growth factors 
 
 
 counteract islet-induced  allo-immune responses by mediating localised suppression of 
the innate and adaptive immune system 
 
To this end, the work as outlined in Chapters 2 and 3 was extended to exploit the observed 
immunomodulatory potential of human amniotic epithelial cells (AEC), employing a 
rotational cell co-culture model to provide these beneficial characteristics to populations of 
isolated, and purified human islets. As AEC are also reported to synthesise and secrete a 
range of growth factors which may have relevance for the sustained functional viability of 
islets (Fiaschi-Taesch et al., 2008, Movassat et al., 2003, Hanley and Rosenberg, 2007, 
Koizumi et al., 2000, Kakishita et al., 2003, Scharfmann and Czernichow, 1996) we also 
explored the impact of AEC co-culture on islet viability and functionality. The effectiveness of 
this intervention was assessed using in vitro models of insulin-secretory function and 
immunomodulation as detailed below. 
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4.2. Materials and Methods  
4.2.1. Bioengineering of islet:AEC constructs 
For co-culture studies islet suspensions obtained as described in section 2.2 were adjusted to 
a density of 500-1000 IEQ per ml and placed under either conventional static culture (CSC) 
conditions in 90mm culture plates (NHS Logistics, Alfreton, UK) or in a rotational cell culture 
system (RCCS) in high aspect ratio vessels (HARVs, Cellon Ltd, Bereldange, Luxembourg).  The 
growth medium for both culture models was composed of Medium-199 (M199) 
supplemented with 10% FBS, 100U/ml penicillin, 100g/ml streptomycin and 10g/ml of 
amphotericin B – no additional trophic factors were added. The cultures were maintained at 
30⁰C in a humidified atmosphere of 95%O2/5%CO2.  Confluent AEC monolayers at passage 1 
were disrupted by mild enzymatic digestion (0.025% trypsin-EDTA in PBS, Sigma-Aldrich Ltd) 
and the resulting cell suspension was washed in PBS and introduced to the islet cultures 
(both CSC and RCCS) at a final density ranging from 1 x 104-1x105 cells per ml. The islet:AEC 
co-cultures were maintained under conditions as described above for 72 hours. The speed of 
rotation of the HARV’s was initially set to 8 rpm and increased to a maximum of 15rpm as 
the size of the islet:AEC aggregates increased.   Control cultures consisted of islets seeded at 
equal density (CSC and RCCS) in the absence of AEC.  
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4.2.2. Immunocytochemical analysis of the islet:AEC constructs 
For immunocytochemistry islet:AEC co-cultures maintained for 72 hours either under CSC 
conditions or within the RCCS were collected into separate centrifuge tubes and centrifuged 
at 400g for 3 mins, the resulting cell pellets being re-suspended in 1ml of supplemented 
RPMI-1640 as previously described for AEC culture.  Autoclaved 13mm glass coverslips were 
placed into each well of a 24-well plate and 0.5ml of supplemented RPMI-1640 was added 
followed by an aliquot of cell suspension containing approximately 20 IEQ or islet:AEC 
aggregates. The well volume was made up to 1 ml by addition of Medium-199 supplemented 
as described above. The islet:AEC constructs were thus allowed to anchor to the glass 
coverslips during a culture period of 48 hours at 37⁰C, 5%CO2, 95%O2. Adhered cell 
aggregates were fixed in freshly prepared 4% paraformaldehyde during a 30 mins incubation 
at RT (Sigma –Aldrich).  Three 10 mins washes in PBS were followed by antigen-retrieval 
(0.3% Triton-X-100, Sigma-Aldrich) and blocking using either 10% normal goat serum (NGS) 
or 10% normal rabbit serum (NRS – both from Vector Laboratories Ltd, Peterborough, UK) 
depending on the species in which the secondary antibody was raised.  The constructs were 
then incubated with the following primary antibodies: anti-human cytokeratin 19 (CK19), 
anti-human vimentin (Dako UK Ltd, Cambridgeshire, UK– 1:100) or anti-human insulin (AbD 
Serotec, Oxford, UK 1:10) for 1 hour at RT and at 4⁰C overnight. Secondary antibody (goat 
anti-mouse IgG-FITC for CK19 and vimentin, goat anti-rabbit IgG-TRITC for insulin – 
Cambridge Biosciences, Cambridge, UK, 1:100) was applied for 3 hours at RT.  The coverslips 
were rinsed and mounted in fluorescence mounting medium (Dako UK Ltd) before cell 
imaging using a Zeiss Axioskop 40 fluorescence microscope equipped with an AxioCam MRC 
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colour camera and incorporating Axiovision imaging software (Carl Zeiss, Hertfordshire, UK).  
Controls involved omission of the relevant primary antibody. 
 
4.2.3. Functional Assessment of the islet:AEC Constructs 
4.2.3.1. Estimation of glucose sensitivity - Static Challenge 
Functional viability of islet:AEC constructs was determined by assessing glucose-stimulated 
insulin secretion (GSIS). Static challenge studies were performed as described in Chapter 2 
with the following modifications:  Constructs (or unmodified islets - controls) were harvested 
from the relevant culture systems by aspiration using a wide bore sterile pastette. The tissue 
suspensions were placed into 15ml conical tubes and centrifuged at 400g for 3 mins, the 
supernatants discarded and the resultant pellets re-suspended in a 2ml volume of 1.67mM 
glucose solution made up in HBSS+0.2%BSA (basal glucose). The tubes containing constructs 
(or unmodified islets) were then placed in a water bath at 37⁰C for 1 hour (pre-incubation 
period). During this hour, a count was performed to determine the number of structurally 
robust islet:AEC aggregates formed during the 72 hour co-culture period.  If necessary the 
islet/islet:AEC suspensions were re-adjusted (by the further addition of the 1.67mM glucose 
solution) to achieve a density of 400 constructs/ml. After the pre-incubation period 50l 
aliquots (equivalent to 20 IEQ/aggregates) of the cell suspension were transferred to 12mm 
x 75mm polypropylene tubes (NHS Logistics, Alfreton, UK) using a pipette fitted with a “cell-
saver” tip to avoid damaging larger constructs. For each culture condition (i.e. CSC vs. RCCS 
islets vs. islet:AEC) a total of 18 tubes were thus prepared, to which 2ml of the appropriate 
secretagogue, diluted in HBSS+0.2% BSA, was added as follows: 6 tubes received 1.67mM 
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glucose solution to assess basal insulin secretion.  To a further 6 tubes a 16.7mM solution of 
glucose was added to determine stimulated insulin secretion. The remaining tubes received 
2ml of 16.7mM glucose supplemented with 10mM theophylline. The racked tubes were 
sealed with parafilm and placed into a water bath at 37⁰C for 1 hour to allow insulin 
secretion (incubation period). Following incubation the tubes were gently vortexed and then 
centrifuged at 400g for 5 mins. The resultant supernatant was harvested for analysis of 
insulin content using an enzyme-linked immunosorbent assay (ELISA; Mercodia, Diagenics 
UK), according to the manufacturer’s instructions. 
 
4.2.3.2. Estimation of Immunomodulatory function – Mixed islet-lymphocyte reaction 
(MILR) 
Islet:AEC constructs were also assessed for immunomodulatory potential in comparison to 
unmodified islets cultured in isolation for the same period. Once adjusted to a final volume 
of approx. 1000 aggregates/ml in supplemented RPMI 1640, 20l of the islet or islet:AEC 
suspension was added to the appropriate wells of a 24-well plate and made up to 1ml total 
volume using the same medium. Thus, approximately 50 IEQ or 50 islet:AEC constructs were 
added to each well and the plate placed at 37°C, 5%CO2, 95%O2 for 72 hours to permit stable 
cell attachment.  Islet: AEC seeded plates were processed by repeated washing in filter 
sterile PBS to ensure all unattached cells/cellular debris was removed from the wells.  
Thereafter, resting or PHA-activated PBMC were added at a density of 50,000 cells/well 
either alone or to wells pre-seeded with firmly anchored islet:AEC  constructs prior to co- 
incubation at 37°C, 5%CO2, 95%O2.   Activated PBMC continued to be cultured in the 
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presence of 5g/ml PHA throughout the assay period. After 72 hours the PBMC were 
harvested, washed and assayed for intracellular ATP content as detailed in Chapter 3. 
 
4.2.4. Statistical Analysis 
Statistical differences in response to insulin secretagogues were assessed by one way 
analysis of variance (ANOVA) using insulin secretion from control islets (islet alone in 
maintained under CSC conditions). Significant differences in PBMC proliferation in response 
to co-culture with islet:AEC constructs was determined using Mann-Whitney U (by Rank) and 
Tukey’s multiple comparison tests, with the response of resting PBMC serving as the control. 
In all comparisons a p value of <0.05 was considered to be statistically significant.  Statistical 
analysis was performed using SigmaStat software version 3.5 (Systat Software Inc, Chicago, 
USA). 
 
 
 
 
 
 
 
 
 
102 
 
4.3. Results I  
4.3.1. Morphological analysis of islet:AEC constructs 
Constructs formed using sub-optimal numbers of AECs (CSC and RCCS) 
In preliminary studies human islets were co-cultured under both CSC conditions and within 
the RCCS employing AEC at low density (less that 5x104/ml). Under these conditions the AEC 
failed to adequately integrate with the islets with limited numbers of AEC attaching to the 
islet surface (Figs. 10 and 11). This was observed in both CSC and RCCS cultures and mirrored 
our observations in Chapter 3 suggesting that AEC require plating at high density to achieve 
adequate attachment to the growing surface. In subsequent studies islet:AEC co-cultures 
were initiated with a minimum of 1x105 cells per ml to encourage optimal cellular 
aggregation of the two cell types.  
 
Islet:AEC constructs formed using optimal AEC density: CSC vs RCCS. 
When a sufficient density of AEC was used in the co-culture system islets and AEC under 
both CSC conditions and within the RCCS demonstrated a degree of cell association: 
However, the extent of cellular integration differed between the two culture conditions. 
When the constructs were formed using static cultures loose aggregates formed with AEC 
overlying the surface of the islet; seemingly using the islet as a matrix (Figs. 12 and 13). 
 
Robust, tightly formed cellular constructs exhibiting good integration of the two cell types 
was achieved when islets and AEC were co-cultured for 72 hours within the RCCS. The vast 
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majority of islets within the RCCS became associated with AEC although, in most instances, 
the AEC did not form a complete layer (Figs.14 and 15).  
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Constructs formed by islet co-culture with sub-optimal numbers of human AEC under 
conventional static culture and within the rotational cell culture system. 
                                                                                
   
 
 
 
 
 
 
 
 
 
 
 
Figures 10. Islet and AEC constructs with a sub-optimal number of AECs cultured under 
conventional static culture (CSC) conditions. Visualisation was achieved using TRITC (red, 
insulin) or FITC (green, CK19) conjugated secondary antibodies (A) phase contrast image of 
the constructs (B) insulin expression (C) CK19 expression (D) overlay image showing very 
poor cellular interaction between islets and AECs 
Scale bar=20m 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. Islet and AEC constructs with a sub-optimal number of AECs maintained in a 
rotational cell culture system (RCCS). Visualisation was achieved using TRITC (insulin) or FITC 
(CK19) conjugated secondary antibodies (A) insulin expression (B) CK19 expression (C) 
overlay image showing very poor cellular interaction between islets and AECs 
Scale bar= 50m 
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Constructs formed by islet co-culture with optimal numbers of human AEC under 
conventional static culture. 
 
 
 
 
B 
 
 
 
Figure 12. Islet and AEC constructs in static culture conditions. Visualisation was achieved 
using TRITC (insulin) or FITC (CK19) conjugated secondary antibodies (A) insulin expression 
(B) CK19 expression (C) overlay image showing some cellular interaction between islets and 
AEC. Scale bar= 50m 
 
 
 
 
 
 
 
 
 
 
 
Figure 13. Islet and AEC constructs in static culture conditions. Visualisation was achieved 
using TRITC (insulin) or FITC (CK19) conjugated secondary antibodies (A) phase contrast 
image of the constructs (B) insulin expression (C) CK19 expression (D) overlay image showing 
some cellular interaction between islets and AECs 
Scale bar=50m 
 
 
A 
 
C 
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Constructs formed by islet co-culture with optimal numbers of human AEC within the 
rotational cell culture system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14. Islet and AEC constructs in rotational culture conditions. Visualisation was 
achieved using TRITC (insulin) or FITC (CK19) conjugated secondary antibodies (A) phase 
contrast image of the constructs (B) insulin expression (C) CK19 expression (D) overlay image 
showing good cellular interaction between islets and AECs and tight robust constructs. Scale 
bar=50m 
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Figure 15. Islet and AEC constructs in rotational culture conditions. Visualisation was 
achieved using TRITC (insulin) or FITC (CK19) conjugated secondary antibodies (A) phase 
contrast image of the constructs (B) insulin expression (C) CK19 expression (D) overlay image 
showing good cellular interaction between islets and AECs and tight robust constructs. Scale 
bar=50m 
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4.4. Results II 
 
4.4.1. Analysis of insulin secretory capacity of islet:AEC constructs  
 
Following a 72 hour period of culture islet and islet:AEC constructs were subjected to further 
glucose challenge studies. Preliminary experiments indicated that isolated AEC do not 
secrete insulin when maintained in either static or rotational culture (data not shown) and 
were therefore not assessed alone during this investigation.  In the presence of elevated 
(16.7mM) glucose, control islets held under CSC conditions throughout the period of the 
investigation responded minimally in terms of insulin secretion (S.I. 1.24±0.07), as previously 
noted (Murray et al., 2009, Murray et al., 2005), although a combination of 16.7mM glucose 
and 10mM theophylline elicited more marked (p< 0.05) insulin secretion (S.I. 1.53±0.1: 
Fig.16).  By contrast, maintenance of islets within the RCCS preserved glucose 
responsiveness with significant insulin secretion occurring in response to 16.7mM glucose 
both in the absence (S.I. 1.59±0.08; p < 0.05) and the presence (S.I. 2.49±0.28; p < 0.01) of 
theophylline.  Co-culture of islets with AEC under both CSC conditions or within the RCCS 
had an apparently beneficial effect on beta cell function, with islets continuing to respond to 
glucose stimulation (S.I. 1.65±0.12 and 2.89±0.34 for islets under CSC condition in response 
to 16.7mM glucose alone and 16.7mM glucose plus 10mM theophylline respectively; S.I. 
1.83±0.11 and 3.15±0.32 for islets maintained in the RCCS in response to 16.7mM glucose 
alone and 16.7mM glucose plus 10mM theophylline respectively: Fig.16).  
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Figure 16.Glucose stimulated insulin release from human islets (HI) maintained under conventional 
static culture (CSC) conditions or within the rotational cell culture system (RCCS) either in the presence 
or absence of human amniotic epithelial cells (AEC) for 72 hours. Insulin release was measured in 
response to 1.67 mmol/l glucose (      ), 16.7 mmol/l glucose (     ), and 16.7 mmol/l glucose plus 10 
mmol/l theophylline (       ).   Results are expressed as the ratio of stimulated insulin release 
compared to basal, mean ± S.E.M. n=4. * p < 0.05 ,    ** p < 0.01 stimulated insulin secretion 
compared to basal  release.  † p < 0.01 for stimulated release in treatment groups compared to the 
control (ANOVA) 
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4.4.2. Analysis of immunomodulatory potential of the islet:AEC constructs 
 
Exposure of resting PBMC to unmodified human islets which were maintained within the 
RCCS elicited a marked (p <0.05) proliferative response (Fig.17.A). The presence of AEC 
attenuated the resting PBMC proliferation elicited by human islets. PHA-stimulated PBMC 
proliferation was increased on contact with isolated islets, but was significantly (p<0.01) 
suppressed when islets were in co-culture with AEC (Fig.17.B). 
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Figures 17.A and 17.B. Modulation of peripheral blood mononuclear cell (PBMC) proliferation by 
exposure to human islets and human islet:AEC constructs:  Resting (A) or PHA-activated (B) human 
PBMC were maintained in 24-well plates either alone or in the presence of human islets (HI) or 
islet:AEC constructs for a period of 72 hours.  The rate of PBMC proliferation following this period 
was measured using an ATP chemiluminescence assay. Data depicts the response from 4 individual 
human islet and AEC preps and represents the typical observation.  * p < 0.01 compared to PBMC 
alone (resting or activated).  † p< 0.01 for PBMC proliferation in response to islet:AEC constructs 
compared to unmodified islets. (Mann-Whitney U) 
 
 
 
 
 
*
†
*
†
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4.5. Discussion 
In previous chapters (2&3) the isolation, culture and morphological and functional 
characterisation of human islets and AEC has been outlined in detail. The experiments 
detailed in the present chapter sought to demonstrate that islet cells may be modified 
through in vitro, pre-transplant interventions designed to enhance post-implant survival; 
specifically, to provide evidence for our hypothesis that the co-culture of human islets with a 
purified population of human amniotic epithelial cells modulates the immunogenic potential 
of transplantable islet cells without impairment of -cell function. The results obtained 
suggest that it is possible to bring these two cell types into close proximity whilst preserving 
their respective insulin secretory function and immunomodulatory capabilities.  
 
This chapter deals therefore, with the impact of co-culturing these two cell types and to 
evaluate their combined function. Notwithstanding their disparate origins, the co-culture of 
human islets and AEC under either conventional static or rotational cell culture conditions 
resulted in successful physical interaction between the two cell types.  The degree of 
association was dependent on the density of AEC seeded with a minimum of 5x104cells/ml 
required before significant aggregation was observed. The observation correlates with our 
earlier findings that AEC require plating at relatively high density in monolayer culture in 
order to achieve good cell attachment and proliferation, which has been reported elsewhere 
(Parolini et al., 2008).  
 
The RCCS provided a more conducive environment for cellular aggregation, with the 
formation of robust constructs exhibiting frequent spatial association of the insulin and CK19 
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expressing cells and a preserved islet-like morphology. The high aspect ratio vessels (HARVs) 
are designed to create a microgravity environment with low shear forces permitting a 
greater degree of cell-cell interaction (Unsworth and Lelkes, 1998) which may underlie the 
efficient formation of stable islet:AEC constructs observed in the present study.  
 
The close proximity of AEC to the human islets had no adverse effect on beta-cell function.  
Indeed, the insulin-secretion data indicate preservation of glucose-sensitivity in human islets 
maintained in co-culture with AEC. This may be compared with islets held alone under CSC 
conditions which showed a diminution of glucose responsiveness. Previous studies 
conducted in this laboratory indicate a beneficial impact of pancreatic ductal-epithelial cell 
co-culture in preserving islet function (Murray et al., 2009), most likely due to their ability to 
provide trophic support to neighbouring beta-cells (Rosenberg and Vinik, 1992). Similarly, 
AEC are reported to synthesise and secrete a range of growth factors which may have 
relevance for the sustained functional viability of islets seen in this novel co-culture model.  
Of note, mRNA expression of TGF, EGF and KGF, known mediators of beta cell replication 
(Fiaschi-Taesch et al., 2008, Movassat et al., 2003, Hanley and Rosenberg, 2007) have been 
reported in intact human amniotic membrane and isolated amniotic epithelial cells (Koizumi 
et al., 2000). Furthermore, dissociated AEC secrete biologically active neurotrophins 
including brain derived neurotrophic factor (BDNF) (Kakishita et al., 2003) which have been 
linked to -cell development and survival (Scharfmann and Czernichow, 1996).  Other 
studies suggest the trophic actions of AEC mediate repair processes in experimental models 
of Parkinson’s Disease, stroke, spinal cord injury and liver fibrosis by encouraging 
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regeneration of host tissue or supporting the growth and engraftment of transplanted cells 
(Parolini and Caruso, 2011) .  
Isolated islets are known to release inflammatory cytokines (including IL-1, IL-6 and 
TNFand pro-inflammatory molecules (including tissue factor and monocyte 
chemoattractant protein-1) which have deleterious effects on -cell function, with 
subsequent impairment of islet graft function (Marzorati et al., 2006, Matsuda et al., 2005). 
Recent studies suggest that AEC exert anti-inflammatory properties as demonstrated in 
animal models of lung and liver fibrosis (Manuelpillai et al., 2011, Manuelpillai et al., 2010a, 
Murphy et al., 2011), reducing the tissue levels of pro-inflammatory cytokines with 
concomitant release of IL-10. It is possible that in our co-culture model these anti-
inflammatory factors serve to subdue cytokine mediated -cell damage thus sustaining islet 
function. Overall, it is likely that the close association of AEC to islets as provided by their co-
culture within the RCCS permits the paracrine release of soluble mediators able to support 
insulin secretory capacity in the post isolation period with beneficial consequences in terms 
of sustained islet graft function. 
 
The proposition that the immunosuppressive properties of isolated AEC may be manipulated 
to confer a state of immune-privilege on other cells capable of provoking an immune 
response is confirmed by the mixed islet-lymphocyte reaction (MILR) study.  Sustained 
proliferation of resting PBMC was demonstrated in the presence of unmodified islets, yet 
those which were closely associated (co-cultured) with AEC failed to elicit an allogeneic 
response.  This effect was not dependent on complete encapsulation of the islets by the 
AEC; further indicative of a role for soluble immunoregulatory factors.  Also, the 
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immunomodulatory response to activated (PHA-stimulated) T-cells was as robust in the 
islet:AEC co-cultures as in AEC monocultures. Combined, these data suggest that AEC exhibit 
a potent and generalised immunosuppressive capability, inducing an anti-proliferative 
response in T-cells subjected both to mitogen and allo-antigen challenge.   
 
This is the first study to demonstrate that the immunomodulatory capabilities of human 
AEC, as observed in vitro, may be conferred on another, otherwise, immunogenic cell 
population, provided that they are held in close proximity. The finding has relevance for the 
wider use of islet cell replacement therapy as a treatment for Type 1 diabetes. The results 
are analogous to contemporary studies where alternative immune-suppressing cell types 
have been co-cultured/co-transplanted with islets, albeit in animal models. Notably, in the 
context of islet transplantation the use of Sertoli cells (SC) to create a local milieu conducive 
to long-term allograft and xenograft survival has been demonstrated experimentally and 
clinically (Isaac et al., 2005, Kin et al., 2002, Valdes-Gonzalez et al., 2007) and more recently 
the use of bone marrow-derived mesenchymal stem cells (MSC) to regulate the 
immunogenicity of islet allografts has also been reported (Ding et al., 2009). We propose 
that immuno-protection could be achieved by the use of AEC, effectively bio-engineering a 
state of immune-privilege within the graft tissue promoting the localised release of soluble 
immunoregulatory mediators.  While the widespread clinical use of human SC and MSC 
would pose certain technical challenges associated with accessibility and standardisation, 
human amnion is readily available and not subject to the same ethical constraints.  
Additionally, the present studies suggest that amnion provides an expandable pool of 
immunomodulatory cells which are amenable to cryopreservation, readily integrate with 
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isolated human islets and do so without causing adverse alterations to beta cell viability, 
cellular transplant volumes or nutrient exchange.  Furthermore, the experimental and 
clinical use of amniotic membrane is well established (Gomes et al., 2005, Hasegawa et al., 
2007, Sheridan and Moreno, 2001, Cargnoni et al., 2009) and successful engraftment of 
human AEC without evidence of tumorigenesis has been reported (Bailo et al., 2004). Direct 
application of this approach awaits “proof-of-concept” studies evaluating the function of 
implanted islet:AEC constructs in immune-competent, diabetic animal models.  
These findings raise the possibility of engineering insulin-secreting tissue constructs 
applicable to cell-based therapies for diabetes, which are capable of restoring endogenous 
insulin production without the need for adjuvant chronic systemic immunosuppression. 
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CHAPTER 5: AEC-MEDIATED IMMUNOMODULATION. 
SPECIFIC T-CELL TARGETS AND RELEVANCE TO ISLET 
TRANSPLANTATION 
 
5.1. Introduction 
 
The previous chapters detailed a series of investigations to demonstrate the potential of 
human AEC to modulate the actions of the immune system. The results suggest that AEC are 
capable of subduing the proliferative activity of human PBMC in response to a known 
mitogen as has been previously reported (Wolbank et al., 2007). Additionally, and for the 
first time, this study provides in vitro evidence that AEC are able to confer their 
immunomodulatory properties to other adjacent cell types with the overall effect of 
reducing the immunogenic profile of, in this instance, human islet cells, and do so without 
impairing function viz. physiological release of insulin. Such a property may have beneficial 
implications for tissue/cell replacement therapy where localised immune-privilege mediated 
by AEC may serve to shield co-transplanted therapeutic cells from immune rejection. At 
present the precise mechanism(s) by which AEC restrict lymphocyte proliferation require 
further elucidation; clinical application of the immunomodulatory actions of AEC would 
benefit from a clearer understanding of the individual T-cell sub-populations targeted by AEC 
and the role that such T-cells play in islet graft rejection.   
 
Our understanding of the mechanism(s) underlying allo and auto-reactivity in islet-cell 
replacement therapy is based on experimental and limited clinical transplantation data. The 
presence of islet-specific autoreactive CD4+ T- cells at time of transplantation coupled with 
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increased frequencies of circulating CD8+ T- cells (insulin B10–18 reactive) is considered to 
significantly influence clinical outcome of islet transplant recipients (Huurman et al., 2008, 
Pinkse et al., 2005). The insulin-specific CD8+ T- cells show potential cytolytic activity, 
producing granzyme B and IFN-γ and are therefore potentially able to destroy insulin-
producing -cells. Equally the absence of these markers, and therefore presumably of auto-
reactivity, correlates with good clinical outcome (Huurman et al., 2008, Pinkse et al., 2005).  
 
Allo-rejection of transplanted islets is considered to be mediated by both CD4+ and CD8+ T-
cells and both populations are required to accomplish -cell death. The actions of a number 
of other immune cells including macrophages, dendritic cells (DC) and B lymphocytes are co-
ordinated to induce and sustain the immune assault. Macrophages and DC act as antigen-
presenting cells and stimulate the migration and infiltration of grafted cells by peripheral 
CD4+ and CD8+ T-cells. The islets are also targeted by natural killer cells (NK) and B 
lymphocytes. Infiltrating macrophages serve to activate cytotoxic CD8+ cells which, in the 
same manner as auto-reactive CD8+ T-cells cause -cell destruction by the release of 
cytolytic agents. In allograft rejection CD4+ T-cells may also act indirectly through B-cell 
activation and the generation of complement fixing antibodies. Pro-inflammatory cytokines 
including interleukin (IL)-12 released by macrophages activate Th1-type CD4+ T-cells which 
subsequently secrete IL-2, interferon-, and TNF- to further augment the CD8+ response.  
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Aims of the Chapter 
As a means of gaining further understanding of the relevance of AEC- mediated 
immunomodulation to islet graft protection the next series of studies sought to more closely 
examine the specific immune cell targets involved. As populations of CD4+ and CD8+ T-cells 
play a major role in both auto and allo-graft rejection this study sought to determine the 
modulatory potential of AEC in regard to these two cell types.   
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5.2. Materials and Methods 
5.2.1. CD4+ T-cell isolation 
A Dynabead®-mediated negative selection system was employed to isolate CD4+ T-cell 
populations (Dynabeads® Untouched™ Human CD4 T-cells, Life Technologies, Paisley, UK). 
The isolation kit is designed to deplete B cells, NK cells, monocytes, platelets, dendritic cells, 
CD8+ T-cells, granulocytes and erythrocytes from platelet-poor PBMC samples, leaving 
isolated CD4+ T- cells free of bead and antibody, thus making them appropriate for use in 
subsequent proliferation assays. In the present study PBMC were isolated from CD leucocyte 
cones (leucocyte concentrates) obtained from healthy donors (NHS Blood and Transplant, 
Birmingham). The cells were processed within 18 hours of blood collection and PBMC 
isolation was performed as described in section 3.3.1.  The PBMC preparation was subjected 
to 3 washes in isolation buffer; Phosphate Buffered Saline (PBS) without Mg2
+ and Ca2
+ 
supplemented with 0.6% sodium citrate and 0.1% BSA. PBMC were counted and adjusted to 
a density of 1x108cells/ml in isolation buffer. A 200l aliquot of the PMBC suspension was 
transferred to a 15ml conical tube to which was added 40l of heat inactivated foetal calf 
serum (FCS, Sigma-Aldrich Ltd). This was followed by addition of 40l of antibody mix 
containing mouse IgG antibodies for CD8, CD14, CD16 (specific for CD16a and CD16b), CD19, 
CD36, CD56, CDw123 and CD235a (GlycophorinA), being sure that the suspensions were 
thoroughly mixed. The cell/antibody suspension was incubated for 20mins at 4°C prior to 
thorough washing in 4mls of isolation buffer. Cells were harvested by centrifugation at 300g 
for 8 mins at 4°C and re-suspended in 200l of isolation buffer. To this was added 200l of 
pre-washed Depletion MyOne® Dynabeads at the same density as the cells, followed by 
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incubation for 15 mins at RT with gentle tilting and rotation using a Hulamixer®.  The bead-
bound cells were re-suspended by vigorously triturating the sample through a 1000l 
pipette tip (approx. 10 times) before addition of 2mls of isolation buffer. The tube containing 
the cells was then placed into a magnet for 2 mins before transferring the supernatant to a 
new tube. The original tube was washed with another 2mls of isolation buffer and returned 
to the magnet. The supernatant was again collected into a fresh tube. Finally the 
supernatants were pooled and placed in the magnet for a further 2 mins to remove any 
remaining beads.  The supernatants containing the free CD4+ cells were then washed in 
isolation buffer and cells harvested by centrifugation at 300g for 5 mins at 4°C prior to 
counting and assessment of viability as described in section 3.3.1. 
 
5.2.2. CD8+ T-cell isolation 
CD8+ T-cells were isolated using a Dynabead®-mediated negative selection system 
(Dynabeads® Untouched™ Human CD8 T-cells, Life Technologies, Paisley, UK) as described 
above for CD4+ T- cells but with the following modifications. 500l of PBMC suspension (at a 
density of 1 x 108cells/ml) were transferred to a 15ml conical tube. The cells were 
supplemented first with 100l of FCS and then with 100l of antibody mix consisting of 
biotinylated mouse IgG antibodies for CD4, CD14, CD16 (specific for CD16a and CD16b), 
CD19, CD36, CD56, CDw123 and CD235a (Glycophorin A) ensuring that cell and antibody 
solutions were well mixed. The cells were incubated for 20 mins at 4°C prior to thorough 
washing in 10mls of isolation buffer. Cells were harvested by centrifugation at 350g for 8 
mins at 4°C and re-suspended in 500l of isolation buffer. To this was added 500l of pre-
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washed Depletion MyOne® Dynabeads followed by incubation for 15 mins at RT with gentle 
tilting and rotation using a Hulamixer®.  The bead-bound cells were re-suspended by 
vigorously triturating the sample before addition of 5mls of isolation buffer. Magnetic 
assisted separation of the bead-bound cells and the resulting purified CD8+ cells were 
harvested, counted and assessed for viability. 
 
5.2.3. Confirmation of T-cell purity by Flow Cytometry 
Purity of the CD4+ T-cell subset was confirmed by cell surface marker labeling and flow cytometry. 
Cell surface staining was achieved by use of a Brilliant Violet 421™conjugated anti-human 
CD4+ antibody or the Isotype control (BioLegend, Supplied by Cambridge Bioscience, 
Cambridge, UK). The antibodies were diluted 1:100 in Fluorescence activated cell sorting 
(FACS) buffer and added to samples of the CD4+ T-cells prior to incubation on ice in the dark 
(covered with foil) for 15 mins. 300l of FACS buffer was then added before centrifugation at 
400g, 4°C, for 5 mins.  The supernatant was removed and replaced with 100l of Fix Buffer 
(made as per manufacturer’s instructions) to each tube, which were incubated on ice for 30 
mins. CD4+ were harvested by centrifugation at 4°C, 400g for 6 mins and washed again with 
300l of FACS Buffer. Following centrifugation at 400g, 4°C for 6 mins, the supernatant was 
removed and the cells were washed 2 times with 200l of Perm Buffer (prepared according 
to manufacturer’s instructions) pelleting between washes by centrifugation 400g, 4°C for 6 
mins. 
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A Cyan 3 laser 9-colour flow cytometer equipped with Summit™ data software (Beckman Coulter, 
High Wycombe, UK) was used to analyse the CD4+ T-cell population on the basis of the forward 
scatter/side scatter profile of cells labelled with BV –anti-CD4+ as detailed above using an isotype-
matched negative control antibody to quantify the degree of positive staining.  
 
5.2.4. Proliferation Studies 
5.2.4.1. CD4+ T-cell proliferation: modulation with phytohaemagglutinin (PHA), human 
amniotic epithelial cells (AEC) 
In preliminary studies we used our existing protocol to determine whether CD4+ T-cell 
proliferation was influenced by exposure to human amniotic epithelial cells (AEC). To this 
end P1 AEC were plated at a density of 5x104/ml into the wells of a 24-well plate and 
incubated at 37°C for 72 hours to enable firm anchorage. CD4+ T-cells, processed as 
described above, were plated at equal density either in the presence or absence of the 
attached AEC. Additionally, further groups of CD4+ T-cells were plated in the presence of the 
plant mitogen phytohaemagglutinin at a concentration of 5g/ml. Incubation was carried 
out at 37°C for 72 hours before the CD4+ T-cells were harvested prior to intracellular ATP 
analysis using chemiluminescence (see section 3.3.4). 
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5.2.4.2. PBMC, CD4+ and CD8+ T-cell proliferation: modulation with anti CD3/CD28, human 
amniotic epithelial cells (AEC) and human islets 
In light of the findings of the preliminary study (detailed in section 5.3.1. below) the next 
series of experiments were performed using a more specific T-cell activation method. 
Dynabeads® Human T-Activator CD3⁄CD28 beads (Invitrogen, Life Technologies, Paisley, UK) 
were employed as an alternative to PHA. CD3/CD28 activator beads are reported to provide 
physiological activation and expansion of human T-cells including CD4+ and CD8+ cells. The 
cells once activated can be analysed or subjected to further differentiation protocols (e.g. 
differentiation to T-helper cells). Proliferation assays were initiated using AEC at P1 plated at 
a density of 5x104cells/well, as described above. Unfractionated PBMC, purified CD4+ or 
CD8+ T-cells were plated at the same density either in the presence or absence of AEC and a 
further group of cells were plated in the presence of 5x104 pre-washed CD3/CD28 activation 
beads. Incubation was carried out at 37°C for 96 hours before the cells were harvested for 
intracellular ATP analysis using chemiluminescence (see section 3.3.4). In a small series of 
experiments mixed islet:lymphocyte proliferation studies were performed. For these studies 
islets were cultured in the presence or absence of AEC in RCCS for 72 hours to allow 
aggregates to form. Islets and islet:AEC constructs were seeded into 24-well plates 
(50IEQ/aggregates per well) and allowed to anchor for up 72 hours. Proliferation assays 
were then established as for the AEC monocultures as described above.  
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5.3. Results 
5.3.1. Expansion of CD4+  T-cell populations using PHA and CD3/CD28 activation beads 
Flow cytometry confirmed the purity of the CD4+ T-cells used in the present studies. In 
preliminary investigations it was observed that isolated CD4+ T-cell populations were largely 
unresponsive to the routinely used stimulator, phytohaemagglutinin (PHA). Whereas 
unfractionated PBMC numbers increased in the presence of 5g/ml PHA, CD4+ T-cell 
numbers did not change significantly. By contrast incubation of both unfractionated PBMC 
and isolated CD4+ T-cells with CD3/CD28 stimulator beads produced a robust increase in 
numbers of both cell populations (Fig 18). In subsequent proliferation studies CD3/CD28 
beads were adopted as the stimulator of choice. 
 
These results were used as the basis for subsequent proliferation assays using fractionated 
CD4+ and CD8+ T-cells. In these studies it was observed that activation of both cell types are 
modulated on co-culture with an equal number of allogeneic human AEC (Fig.19). Resting 
CD4+ and CD8+ T-cells were largely unresponsive to co-culture with allogeneic AEC but 
responded robustly to the presence of an equal number of CD3/CD28 activator beads. The 
degree of T-cell expansion induced by the beads was significantly (p < 0.01) abrogated in the 
presence of allogeneic AEC with a greater than 50% inhibition for both T-cell populations 
(Fig.19). 
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5.3.2. Fractionated CD4+ and CD8+ T-cell proliferation assays. Impact of co-culture with 
human AEC 
This series of studies first sought to determine whether human AEC are able to modulate the 
proliferative capacity of fractionated CD4+ and CD8+ T-cells. As observed with PBMC, 
allogeneic AEC failed to provoke significant CD4+ T-cell proliferation when co-cultured at 
varying densities ranging from 2.5x103-5x104. Employing CD3/CD28 activator beads as the 
stimulus, AEC-mediated inhibition of CD4+ T-cell proliferation was observed at all ratios 
tested from 1:20 – 1:1, exhibiting a degree of dose-dependency (Fig.20). 
 
5.3.3. Response of CD4+ and CD8+ T-cell populations on co-culture with allogeneic human 
islets and islet:AEC constructs 
In a limited study human islets prepared as outlined in Section 2.2. were used in a mixed 
islet:lymphocyte reaction. In vitro, allogeneic human islets provoked a moderate activation 
of both CD4+ and CD8+ T-cells (Fig 21). Expansion of both T-cell populations was observed 
during a 96 hour co-culture period with human islets. By contrast, when human islets were 
pre-cultured with human AEC to form constructs as detailed section 4.2.1, the response of 
CD4+ of CD8+ cells was significantly attenuated (Fig.21). 
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Figure 18. Activation of PBMC (A) and fractionated CD4+ T-cells (B) on exposure to either 
phytohaemagglutinin (PHA - 5g/ml) or an equal number (5x104) of CD3+/CD28+ activation beads. 
PHA produced a robust increase in PBMC numbers but a greater response was observed in both cell 
populations when the activator beads where employed as the stimulus. n = 4. * p < 0.05, **p < 0.01 
compared with control (resting cells). One way ANOVA 
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Figure 19. Modulation of CD4+ and CD8+ T-cell proliferation by allogeneic human amniotic epithelial 
cells (AEC): Resting (rs ) or CD3/CD28-activated (st ) CD4+(blue shaded bars), and resting (rs )or 
CD3/CD28-activated (st ) CD8+ (green shaded bars)T-cells were maintained in 24-well plates either 
alone, or in the presence of an equal number of human amniotic epithelial cells for a period of 96 
hours.  The rate of T-cell proliferation following this period was measured using an ATP 
chemiluminescence assay. Data shows the percentage increase above control (resting T-cell). n = 3.    
* p < 0.05, ** p < 0.01 compared to control.  † p< 0.01 for CD3/CD28-activated T-cell proliferation in 
the presence or absence of AEC. (Mann-Whitney U and Tukey’s multiple comparison tests) 
 
 
 
 
0
500
1000
1500
2000
CD4+ (rs) CD4+ (st) CD4+ (rs) + 
AEC
CD4+ (st) + 
AEC
CD8+ (rs) CD8+ (st) CD8 (rs) + 
AEC
CD8 (st) + 
AEC
T
-
ce
ll
 P
ro
li
fe
ra
ti
o
n
 (%
 c
o
n
tr
o
l)
Experimental Group
**
**
*
*
†
†
129 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Dose-dependent modulation of CD4+ T-cells on co-culture with human amniotic epithelial 
cells (AEC): AEC were pre-plated at densities ranging from 2.5x103-5x104 cells/well and co-cultured 
with 5x104 CD4+ T-cells for 96 hours. Cell proliferation was measured by chemiluminescence assay. n 
= 3. * p < 0.05, ** p< 0.01 for CD4+ T-cell proliferation in the presence vs. absence of AEC. One way 
ANOVA  
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Figure 21. Modulation of CD4+ and CD8+ T-cell proliferation by exposure to human islets and human 
islet:AEC constructs:  Resting CD4+ T-cells (blue bars) and CD8+ T-cells (green bars) were maintained 
in 24-well plates either alone or in the presence of human islets (HI) or islet:AEC constructs (HI/AEC) 
for a period of 96  hours.  The rate of T-cell proliferation following this period was measured using an 
ATP chemiluminescence assay. Data depicts the response from 2 individual human islet and AEC 
preps and represents the typical observation.  * p < 0.01 compared to resting levels.  † p< 0.01 for T-
cell expansion in the presence of HI/AEC constructs compared to HI alone. (Mann-Whitney U and 
Tukey’s multiple comparison tests) 
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5.4. Discussion 
This investigation provides further evidence that the immuno-modulatory potential of 
human AEC may have relevance to the protection of islet allografts from immune assault. 
The findings suggest that several of the targets of AEC-induced immunomodulation have 
relevance to islet allograft rejection and as such indicate the potential use of AEC 
populations as mediators of “bystander” immunosuppression in islet transplantation. The 
data indicate that both CD4+ and CD8+ T-cell activation is responsive to AEC and that 
bringing these immune cells into close proximity of AEC prevents their in vitro expansion in 
response to a physiological stimulus viz. CD3/CD28 complex. As the activation and 
proliferation of CD4+ and CD8+ T-cells is crucial to the appropriate and successful activation 
of the innate and adaptive immune response, culminating in allograft rejection, suppression 
of their function by AEC may have relevance for providing a localised means of providing 
immune protection to transplanted islet cells and circumvent the need for long-term, non-
specific systemic immunosuppression. 
 
The lack of responsiveness of fractionated CD4+ T-cells to the routinely used mitogen PHA 
prompted modification to the protocol for assessing AEC-mediated modulation in the 
present chapter. The failure of PHA to cause significant CD4+ T-cell expansion at a 
concentration which effectively increased PBMC numbers indicates that accessory cell 
populations (i.e. macrophages, dendritic cells) may be required for appropriate CD4+ 
stimulation in the presence of this mitogen. Indeed it has been reported that CD4+ T-cells 
fail to express IL-2 receptor (CD25) or respond appropriately to IL-2 in the absence of cells 
involved in antigen presentation and as a result, expansion of T-cell population is blunted 
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(Halvorsen et al., 1988, Leivestad et al., 1988). Hence it was necessary when conducting 
studies with purified CD4+ and CD8+ populations to use a stimulus which would provide the 
required antigen presentation and which also has relevance in terms of clinical application. 
Immuno-magnetic anti-CD3 anti-CD28 coated beads are employed for in vitro T-cell 
expansion prior to infusion in immunotherapy (Thompson et al., 2003). Commercially 
available expansion beads seek to mimic physiological activation of CD4+ and CD8+ T-cells by 
simulating in vivo T-cell proliferation in response to antigen-presenting cells. The system 
utilizes the two activation signals CD3 and CD28, bound to a three-dimensional bead similar 
in size to endogenous antigen-presenting cells. Thus this method provides appropriate T – 
cell activation without the need to re-introduce macrophages/dendritic cells which may 
themselves be directly or indirectly modulated by contact with human AEC.  
 
Having made changes to the protocol it was possible to clearly demonstrate that CD4+ and 
CD8+ T-cell proliferation, similarly to unfractionated PBMC, was abrogated by co-culture 
with AEC. In contrast to the results with unsorted PBMC, we observed a relatively small 
increase in CD4+ and CD8+ T-cell numbers under basal conditions which could be indicative 
of a mild allogeneic response.  However, as AEC are also a source of many trophic factors 
(Parolini and Caruso, 2011) it is also possible that the increase in cell numbers under resting 
conditions reflects the generalised cell-supportive characteristics of AEC/AEC-conditioned 
medium which may serve to promote survival of purified resting T-cells and reduce the basal 
rate of apoptosis. 
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The results of the initial mixed islet:lymphocyte study suggests that CD4+ and CD8+ cells are 
activated by islet allo-antigens. The subdued nature of their response to islet co-culture may 
be due to the decline of immunogenicity and depletion of carrier (host-derived) dendritic 
cells which occurs in human islets during prolonged culture, especially within the RCCS 
(Rutzky et al., 2002). Yet, elevated CD4+ and CD8+ T-cell numbers were observed during    
T-cell:islet co-culture but this increase was abrogated in the islet:AEC constructs as 
demonstrated in Chapter 4.  
 
There is a general consensus, based on studies in experimental islet transplantation that 
both CD4+ and CD8+ T-cells are involved islet allograft rejection with initial infiltration of 
antigen-presenting cells, such as macrophages and DC mediating the response. The release 
of cytokines notably IL-2 and IL-6 trigger lymphocyte activation and the migration of CD4+ 
and CD8+ T-cells to the site of the graft. Additional pro-inflammatory cytokines secreted by 
CD4+ T-cells prompt the invasion of NK cells and B lymphocytes which on activation 
generate complement fixing antibodies. CD8+ cytotoxic cells cause further -cell damage by 
the release of chemicals granzymes and perforins which induce cell lysis. The allogeneic 
response is exacerbated by pro-inflammatory cytokines released by activated Th1 type CD4+ 
T-cells which secrete IL-2, interferon-, and TNF- which maximise CD8+ activation.  
 
To summarise, in combination the immunoregulatory properties of AEC have the capacity to 
influence several aspects of immune-mediated destruction of the islet graft. Firstly they may 
directly induce apoptosis of CD4+ and CD8+ T-cells by the actions of soluble FasL and HLA-G.  
Whilst the Fas/FasL pathway is normally associated with CD8+ mediated cell destruction, 
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and has the propensity to activate neutrophil-mediated inflammation (Turvey et al., 2000) 
the presence of FasL bearing AEC may become dominant in a microenvironment in which the 
Th1/Th2 ratio is in favour of Th2 cells and therefore anti-inflammatory mediators 
predominate (Pearl-Yafe et al., 2006). The secretion of TGF- and IL-10 by AEC may also 
serve to prevent the activation and proliferation of T effector cells and inhibit the production 
of pro-inflammatory cytokines. Additionally, AEC also secrete macrophage inhibitory factor, 
reducing the magnitude of immune cell migration and therefore graft infiltration (Li et al., 
2005) 
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CHAPTER 6: FUTURE WORK, GENERAL DISCUSSION AND 
CONCLUSIONS 
 
 
Diabetes mellitus is a metabolic disorder resulting in hyperglycaemia and the onset of 
secondary complications, which are in turn associated with significant morbidity and 
mortality. The pharmacological approach to its treatment (insulin, oral hypoglycaemics) 
serves to manage the condition, but is not a cure and does not provide full protection from 
the potentially life-threatening consequences of the disease. The definitive therapeutic 
strategy for T1DM is the re-instatement of endogenous insulin production to restore 
physiological glucose control. Both whole organ viz. pancreas and islet cell transplantation 
offer the recipient the possibility to achieve and maintain euglycaemia and since the early 
2000s and the introduction of the Edmonton protocol, islet transplantation outcomes have 
improved significantly where 1- year insulin-independence rates have reached 70% to 90% in 
experienced transplant centres (Shapiro et al., 2006). Yet whilst early results are good, 
current protocols are still associated with a progressive and steady decrease in graft 
function; up to 90% of recipients return to insulin therapy within 5 years of their first 
infusion (Ryan et al., 2005). 
 
As discussed in Chapter 1, the underlying cause of islet graft attrition is likely to be 
multifactorial, involving recurrence of autoimmunity, allogeneic rejection, toxicity of the 
immunosuppressive drug regimen, poor graft re-vascularisation and “metabolic fatigue” of 
the islet graft. Determining the precise cause of graft failure in each clinical case is restricted 
by the limitations in technology for monitoring transplanted islets although much research is 
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now concerned with graft imaging and surveillance for signs of immunologic events in the 
peripheral blood (Berney and Toso, 2006). The impact of immune-mediated -cell loss is, 
however, likely to be significant, with studies indicating an association between pre-
transplant cellular auto-reactivity and poor clinical outcome (Huurman et al., 2008). 
Furthermore, in case studies graft failure is demonstrated to be preceded by the detection 
of antibodies to HLA class II antigens (Kessler et al., 2009).   
 
Immunosuppressive drugs fall short of producing long term graft protection and additionally, 
expose the recipient to toxicity, increased vulnerability to infection and heightened 
susceptibility to malignancy. These risks are factored into the pre-operative 
evaluation/assessment of potential islet transplant recipients, being balanced against the 
potential benefits of the procedure in terms of reducing insulin requirement, providing good 
glucose control and limiting the frequency of hypoglycaemic events by restoring 
hypoglycaemic awareness. Such considerations invariably result in only the most poorly 
controlled diabetic individuals being selected for transplant, and then only after intensive 
insulin therapies have been explored, including the use of insulin pumps. If islet 
transplantation is to be made more readily available, becoming a routine treatment option 
for diabetes, it is of paramount importance to develop more long term, effective and safe 
methods of islet graft immuno-protection. 
 
This thesis seeks to provide preliminary evidence in support of the clinical exploitation of 
immune-privileged tissue to locally control the recipient immune response in cellular 
transplantation. The unique features of the islet graft viz. discrete cell clusters transplanted 
137 
 
in a relatively small volume means that it may be possible to avoid chronic, systemic 
immunosuppression by pre-transplant modification of the graft combined with manipulation 
of the implantation site. Human amniotic epithelial cells (AEC) are chosen as a potential 
candidate for this role due to certain key characteristics, notably their immune inertness on 
transplantation and ability to markedly reduce T-cell proliferation as demonstrated in this 
study (Chapter 3) and by others (Parolini et al., 2008). The present study is the first to seek 
to capitalise on these features of AEC in the context of islet transplantation and to provide 
direct (in vitro) evidence that AEC are capable of modulating the immunogenicity of human 
islets to the T-cells directly implicated in graft rejection (Chapter 4&5).  
 
Complete characterisation of the mechanisms underlying the immunosuppressive potential 
of AEC will form the basis of future work. Our current understanding of the properties of AEC 
will determine which potential mechanisms merit closer investigation. Special attention 
should be paid to the possibility that the unique repertoire of soluble mediators secreted by 
AEC create graft tolerance either by a direct cytotoxic effect on CD4+ and CD8+ T-cells 
(potentially via soluble HLA-G) (Pratama et al., 2011, Hammer et al., 1997) or more 
interestingly, by the induction of regulatory T-cells (T-regs).  Increasingly, regulatory T-cells 
(CD4+/CD25+/Foxp3 regulatory T-cells) are being implicated in the suppression of allogeneic 
graft rejection and the development of immune-tolerance (Wood, 2011, Wood et al., 2003).  
In the periphery T-regs are derived from naïve CD4+ cells and are thought to arise as a 
consequence of appropriate exposure to antigen and co-stimulation in the presence of 
cytokines which induce expression of Foxp3, a gene which, in turn, orchestrates T-reg 
expansion. AEC secrete two cytokines considered to be implicated in the induction of Foxp3 
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namely transforming growth factor beta (TGF- and IL-10 (Manuelpillai et al., 2010b, 
Pothoven et al., 2010, Chung et al., 2009, Li et al., 2005)and are therefore capable, at least 
in theory, of creating a local environment conducive to the expansion of T-reg populations.  
In the context of islet transplantation AEC could induce the expression of alloantigen-specific 
T-regs able to counteract the deleterious effects of CD4+ and CD8+ T-cells and therefore 
prevent graft rejection and mediate link unresponsiveness. To test this theory, future studies 
using T-cell proliferation assays would be conducted to detect changes in the levels of Foxp3 
expression, by flow cytometry, in CD4+ T-cells cultured in the presence or absence of 
dispersed AEC and AEC supernatant, and also with islet:AEC constructs. Subsequent studies 
would attempt to correlate changes in Foxp3 expression to the prevailing levels of TGF- and 
IL-10 in the assay supernatant, and further validate their role by addition of TGF- and IL-10 
antibodies to block Foxp3 induction.  
 
Additional potential targets for AEC- mediated immunosuppression include restriction of 
dendritic cell maturation (Li et al., 2006b) and inhibition of T-cell proliferation by 
indoleamine 2,3 dioxygenase (IDO) via tryptophan depletion (Jones et al., 2007) which may 
also be explored as part of ongoing studies. 
 
The islet:AEC constructs bioengineered in the present study exhibit both insulin-secretory 
and immunomodulatory capabilities (Chapters 4&5). These two characteristics make 
islet:AEC constructs ideal for use in cell replacement therapy for the treatment of diabetes. 
In future work an assessment of their ability to survive and perform under experimental, 
physiological conditions must be undertaken using animal models, thus providing “proof-of-
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concept”. A positive outcome would provide the necessary rationale for studies in higher 
non-human primates prior to transferring the technology to a clinical setting. 
 
The series of in vivo studies would include assessment of construct survival in both immune-
deficient and immune-competent murine models using the renal sub-capsular space as the 
implant site and detection of circulating human C-peptide and insulin as indicators of graft 
function. Additional studies in diabetic murine models (streptozotocin-treated and non 
obese diabetic – NOD) will confirm the ability of the islet:AEC constructs to restore and 
maintain normoglycaemia in the absence of chronic immunosuppression. Appropriate 
histological examination of explanted tissue i.e. haematoxylin and eosinophil staining, 
immunocytochemical localisation of human insulin, glucagon, E-cadherin, and infiltration of 
murine CD4+, CD8+ and Foxp3 positive cells will further define the degree of graft survival 
and increase our understanding of the mechanism(s) underlying graft immuno-protection.  
 
It is envisaged that the clinical use of modified islets whether by co-aggregation with human 
AEC, bone marrow-derived mesenchymal stem cells or other immunomodulatory cell 
populations would ultimately operate in conjunction with other novel strategies of graft 
immuno-protection. It is feasible to suggest that during the initial transplant period 
additional methods of immune protection would be required, giving the AEC time to 
establish and exert influence at the site of implantation. The putative mechanism(s) 
underlying AEC-mediated immunosuppression may well be compatible with some of the 
newer methods of graft protection currently being explored, including co-stimulation 
blockade (notably the CD28/CD80/86 and CD40/CD154 pathways) and the use of anti-CD3 or 
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T-cell depleting antibodies (Bellin et al., 2012). Their use as induction therapy in conjunction 
with islet:AEC co-grafting may circumvent the need for the use of calcineurin inhibitors 
(tacrolimus) and other more conventional immunosuppressive agents (sirolimus) and 
therefore eliminate their attendant toxic actions both on the graft and the recipient. 
 
Whilst islet transplantation continues to be defined as a research or experimental treatment 
it delivers real improvements both to the health status and quality of life of graft recipients. 
Unquestionably, there is a need to refine the technique, reducing the risk:benefit ratio and 
improving long term clinical outcome if islet transplantation is to become a serious rival to 
exogenous insulin therapy. The work detailed in the present thesis provides a rationale to 
examine novel cell-based strategies for islet graft immune protection, which may in time, 
contribute to a more effective means of ensuring sustained islet graft survival. 
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Human Amniotic Epithelial Cells Induce Localized Cell-Mediated Immune
Privilege In Vitro: Implications for Pancreatic Islet Transplantation
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Hilary E. Murray,* Clifford J. Bailey,† and Richard Downing*
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Chronic systemic immunosuppression in cell replacement therapy restricts its clinical application. This study
sought to explore the potential of cell-based immune modulation as an alternative to immunosuppressive
drug therapy in the context of pancreatic islet transplantation. Human amniotic epithelial cells (AEC) possess
innate anti-inflammatory and immunosuppressive properties that were utilized to create localized immune
privilege in an in vitro islet cell culture system. Cellular constructs composed of human islets and AEC
(islet/AEC) were bioengineered under defined rotational cell culture conditions. Insulin secretory capacity
was validated by glucose challenge and immunomodulatory potential characterized using a peripheral blood
lymphocyte (PBL) proliferation assay. Results were compared to control constructs composed of islets or
AEC cultured alone. Studies employing AEC-conditioned medium examined the role of soluble factors, and
fluorescence immunocytochemistry was used to identify putative mediators of the immunosuppressive re-
sponse in isolated AEC monocultures. Sustained, physiologically appropriate insulin secretion was observed
in both islets and islet/AEC constructs. Activation of resting PBL proliferation occurred on exposure to
human islets alone but this response was significantly (p < 0.05) attenuated by the presence of AEC and
AEC-conditioned medium. Mitogen (phytohaemagglutinin, 5 µg/ml)-induced PBL proliferation was sus-
tained on contact with isolated islets but abrogated by AEC, conditioned medium, and the islet/AEC con-
structs. Immunocytochemical analysis of AEC monocultures identified a subpopulation of cells that ex-
pressed the proapoptosis protein Fas ligand. This study demonstrates that human islet/AEC constructs exhibit
localized immunosuppressive properties with no impairment of β-cell function. The data suggest that trans-
planted islets may benefit from the immune privilege status conferred on them as a consequence of their
close proximity to human AEC. Such an approach may reduce the need for chronic systemic immunosup-
pression, thus making islet transplantation a more attractive treatment option for the management of insulin-
dependent diabetes.
Key words: Human islets; Human amniotic epithelial cells; Immune privilege; Rotational cell culture system;
Peripheral blood lymphocytes; Immunosuppression; Insulin; Fas ligand
INTRODUCTION immune isolation that circumvents the need for systemic
immunosuppression has been the subject of extensive
research. Macro- and microencapsulation devices haveIslet transplantation offers a more physiological ap-
proach to the restoration of glucose homeostasis than been the preferred option, resulting in limited clinical
application (6,39), but loss of capsule integrity and im-exogenous insulin therapy (8,30), but its use is restricted
to a discrete population of individuals with type 1 diabe- paired gaseous and nutrient exchange undermine long-
term β-cell function. Nanocapsule devices, formed fromtes who experience frequent and unpredictable episodes
of hypoglycemia. More widespread application of islet layers of biocompatible polymer applied to the islet sur-
face, address some of these limitations, but the processtransplantation awaits solution of technical limitations,
in particular the requirement for chronic systemic immu- is technically involved and incurs significant loss of β-
cell mass (35,40). Hence, a clinical role for encapsulatednosuppression, which poses risks both to the islet graft
and its recipient (4,11,17,32). islet transplants must await improvements in capsule
composition and biocompatibility.Development of a safe, biocompatible method of islet
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A more physiological approach to cellular immune Research Ethics Committee approval. A total of seven
pancreases (five female, two male; mean age 47.1 ± 3.3evasion exploits the properties of cells with innate im-
munomodulatory capabilities involved in creating ana- years) were used, with an average cold ischemic time of
10.04 ± 1.25 h. Organs were dissociated by a combina-tomical sites of immune privilege. Sertoli cells (SC) in-
duce a state of immune neutrality in the testis to support tion of enzymatic digestion (Liberase HI, Roche Diag-
nostics, West Sussex, UK) and mechanical agitation,resident germ cells and prevent rejection of allogeneic
and xenogeneic intratesticular islet grafts. Furthermore, and islets separated from the resulting pancreatic digest
using density gradient centrifugation on Ficoll columnsSCs may also confer immune privilege at anatomical
sites that would otherwise be unable to sustain graft sur- as previously described (26,27). Staining with dithizone
(500 µg/ml, Sigma Aldrich Ltd, Dorset, UK) was usedvival without systemic immunosuppression. When preen-
grafted to the renal capsule of chemically induced dia- to assist islet counting and conversion to islet equiva-
lents (IEQ) (28), while trypan blue (0.4% v/v) exclusionbetic mice, SCs enhance subsequent islet allograft
survival (20); examples of xenograft protection at ec- confirmed islet cell viability. The islet preparations were
seeded at a density of 750–1000 IEQ/ml in Medium 199topic sites in large mammals have also been documented
(16). Intriguingly, such studies suggest that complete en- containing 100 U/ml penicillin, 100 µg/ml streptomycin,
10 µg/ml amphotericin B (Sigma Aldrich Ltd) supple-capsulation of islets by SC is not a prerequisite to pre-
vent rejection; nonetheless, obtaining sufficient numbers mented with 10% fetal calf serum (First Link Ltd, Bir-
mingham, UK), and maintained in nonadherent cultureof SC for use in human transplantation would pose lo-
gistical challenges. (27) for a period of 24 h to allow acclimatization.
Human fetal membranes may provide an alternative Human Amniotic Epithelial Cell (AEC) Isolation
source of immunoregulatory cells, readily obtainable in Human amniotic membrane was obtained accordinglarge numbers without ethical constraints. Amniotic
to ethically approved protocol and with informed con-
membrane possesses anti-inflammatory and immune-
sent from 17 women (mean age, 32.5 ± 1.6 years) under-
suppressing properties that underlie its clinical use in the going elective Caesarean section. Samples (10 × 10 cm)
treatment of wounds, burns, and in ophthalmic surgery
of amniotic tissue were separated from the chorion layer
where it is grafted without rejection (2,9,14,33). Human by blunt dissection (avoiding areas overlying the pla-
amniotic epithelial cells (AEC) isolated from the mem-
centa). The tissue was rinsed three times in phosphate-brane suppress T-cell activation in both mixed and mito- buffered saline (PBS, Sigma Aldrich Ltd) containinggen-induced lymphocyte proliferation assays (24,41): 200 U/ml penicillin, 200 µg/ml streptomycin, and 20AEC are amenable to both allogeneic and xenogeneic µg/ml amphotericin B, and reduced to small pieces for
engraftment in immune-competent recipients (1,22). The digestion in 0.25% (w/v) trypsin in Hanks balanced salt
expression of potential mediators of immune suppres-
solution (HBSS, Sigma-Aldrich Ltd) for 20 min at 37°C.
sion, including HLA-G, Fas ligand and TGF-β have The resulting tissue suspension was passed through abeen identified in human AEC (13,23,24), which may 500-µm mesh to retain larger pieces of amnion, which
serve to inhibit immune cell functions to create a micro-
were subjected to three further incubation cycles with
environment conducive to allogeneic graft survival.
trypsin to liberate all available epithelial cells. PooledIn the present study we examined the potential of hu- fractions of cell suspension thus obtained were centri-
man AEC to modify the immune response to isolated fuged at 400 × g for 5 min and the pellets resuspendedhuman islets. Specifically, we sought to test the hypoth- in RPMI-1640 supplemented with 10% fetal bovine se-
esis that the presence of AEC in close proximity to hu-
rum (FBS, Sigma-Aldrich Ltd), 100 U/ml penicillin, 100
man islets alters the immediate microenvironment suffi- µg/ml streptomycin, and 10 µg amphotericin B. AEC
ciently to induce a localized immunosuppressive
were seeded at high density in T-75 flasks and cultured
response on invading peripheral blood lymphocytes. A
at 37°C, 5% CO2, 95% O2 in a humidified atmosphererotational cell culture system (RCCS) (26,27) was em- for 48–72 h, to form a flattened confluent monolayer.ployed to bioengineer novel cellular constructs com- In some instances cultures of AEC harvested at conflu-posed of islets and AEC (islet/AEC), the functional and
ence by mild trypsinization (0.025% trypsin-EDTA inimmunological characteristics of which were then inves- PBS, Sigma Aldrich Ltd) were resuspended in supple-
tigated under in vitro conditions.
mented RPMI containing 10% DMSO and cryopre-
served at −80°C for later analysis of immunomodulatoryMATERIALS AND METHODS
potential.Human Islet Isolation
Peripheral Blood Lymphocyte (PBL) IsolationPancreases from multiorgan donors were supplied by
the UK Human Tissue Bank (De Montfort University, Peripheral blood lymphocytes (PBL) were isolated
from buffy coats obtained from nine healthy volunteersLeicester, UK) with the appropriate consent and local
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through the National Blood Service (NBS, Birmingham, antibody (goat anti-mouse IgG-FITC for CK19, vimen-
tin, and FasL, goat anti-rabbit IgG-TRITC for insulin;UK) with local research ethics approval. Briefly, buffy
coat fractions were resuspended in an equal volume of Cambridge Biosciences, Cambridge, UK, 1:100) was ap-
plied for 3 h at RT. The coverslips were rinsed andHBSS and layered onto 12 ml of Histopaque-177
(Sigma-Aldrich Ltd), centrifuged at 700 × g for 30 min mounted in fluorescence mounting medium (Dako UK
Ltd) before cell imaging using a Zeiss Axioskop 40 fluo-(with no brake), and the resulting leucocyte layer har-
vested using a sterile pastette. The isolated PBLs were rescence microscope equipped with an AxioCam MRc
color camera and incorporating Axiovision imagingwashed three times in HBSS, centrifuged at 500 × g for
10 min, resuspended in RPMI-1640 (supplemented as software (Carl Zeiss, Hertfordshire, UK). Controls in-
volved omission of the relevant primary antibody.described above), and cultured in uncoated plastic petri
dishes at 37°C, 5% CO2, 95% O2 overnight. A portion Insulin Secretory Capacity: Static Glucose Challengeof the isolated PBLs was incubated with the mitogen
Cultures of islets or cocultures consisting of isletsphytohemagglutinin (PHA, 5 µg/ml, Sigma Aldrich Ltd)
and AEC maintained either under CSC conditions orfor 24 h prior to use in proliferation assays.
within the RCCS as described above were assessed for
Islet/AEC Coculture: Conventional Static Culture preserved glucose responsiveness. The impact of culture
Versus a Rotational Cell Culture System (RCCS) condition on islet function was determined by measuring
insulin release in response to glucose under basal condi-For coculture studies islet suspensions were adjusted
tions viz. in the presence of 1.67 mmol/L glucose into a density of 500–1000 IEQ/ml and placed under ei-
modified HEPES-buffered HBSS comprised of (mmol/L):ther conventional static culture (CSC) conditions in 90-
HEPES (9.9); NaCl (113.2); NaHCO3 (4.1); Na2HPO4mm culture plates (NHS Logistics, Alfreton, UK) or in
(0.33); KCl (5.36); CaCl2 (0.95); MgSO4.7H2O (0.8);a rotational cell culture system (RCCS) in high aspect
KH2PO4 (0.44), containing 0.2% BSA, pH 7.4, at 37°C,ratio vessels (HARVs, Cellon Ltd, Bereldange, Luxem-
and subsequent to stimulation with high glucose (16.7mmol/bourg) as previously described (27). The cultures were
L) or a combination of 16.7 mmol/L glucose and 10maintained at 30°C in a humidified atmosphere of 95%
mmol/L theophylline according to methods previouslyO2/5% CO2. Once confluent the AEC monolayers were
described (26,27). The secretory capacity demonstrateddisrupted by mild enzymatic digestion (0.025% trypsin-
by islets maintained under CSC conditions was com-EDTA in PBS, Sigma Aldrich Ltd) and the resulting cell
pared with that seen in islets held within the RCCS andsuspension washed in PBS and introduced to the islet
to islets in coculture with AEC under both culture condi-cultures (both CSC and RCCS) at a final density of 1 ×
tions. Response to glucose stimulation was quantified by105 cells/ml. The islet/AEC cocultures were maintained
measurement of insulin in the incubation medium usingunder conditions as described above for 72 h. Control
a commercial ELISA (Diagenics Ltd, Milton Keynes,cultures consisted of islets seeded at equal density (CSC
UK) and expressed as a ratio of insulin secretion underand RCCS) in the absence of AEC.
basal conditions (stimulation index, SI). The islets were
Morphological Analysis of AEC Monocultures assessed for insulin secretory capacity at 24 h postisola-
and Islet/AEC Cocultures Using tion and at 72 h after the initiation of the islet/AEC co-
Fluorescence Immunocytochemistry cultures (viz. 5–7 days postisolation).
For immunocytochemistry isolated AEC and islet/
Immunomodulation: PBL Proliferation AssayAEC cocultures maintained for 72 h either under CSC
conditions or within the RCCS were anchored to glass AEC Monocultures. Confluent monolayers of AEC
were dispersed and transferred to 24-well plates at a fi-coverslips and fixed with 4% paraformaldehyde for 30
min at room temperature (RT). Three 10-min washes in nal density of 5 × 104 cells/well in supplemented RPMI
as described above. The cells were allowed to attach andPBS were followed by antigen retrieval (0.3% Triton X-
100, Sigma Aldrich Ltd) and blocking (10% normal goat flatten prior to the initiation of PBL proliferation assays.
Resting or PHA-activated PBLs were added to each wellserum in PBS for CK19, vimentin, FasL; 10% normal
rabbit serum in PBS for insulin, Vector Laboratories at equal density (5 × 104/well) for coincubation at 37°C,
5% CO2, 95% O2. Activated PBLs in contact with AECLtd, Peterborough, UK). The AEC or islet/AEC con-
structs were then incubated with primary antibodies, continued to be cultured in the presence of 5 µg/ml
PHA. After 72 h the PBLs were harvested, solubilizedanti-human cytokeratin 19 (CK19), anti-human vimentin
(Dako UK Ltd, Cambridgeshire, UK; 1:100), anti- (VialightPlus, cell lysis reagent, Lonza Ltd, Woking-
ham, UK), and analyzed for ATP content using a com-human insulin (AbD Serotec, Oxford, UK; 1:10), or
anti-human Fas Ligand (FasL, CD95L, Sigma Aldrich mercial chemiluminescence assay (Lonza Ltd) according
to the manufacturer’s instructions. Concentration ofLtd, 1:10) for 1 h at RT and at 4°C overnight. Secondary
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ATP per well, measured as relative light units (RLU), is statistically significant. Statistical analysis was per-
formed using SigmaStat software version 3.5 (Systatdirectly proportional to cell number and thus indicative
of the proliferative activity of PBLs in culture (34). Re- Software Inc, Chicago, IL, USA).
sults were expressed as a percentage of control (i.e.,
RESULTSresting PBLs incubated in the absence of AEC). In se-
Morphological and Immunocytochemical Assessmentlected experiments cryopreserved AEC were rapidly
of Human Islet and Amniotic Epithelialthawed, rinsed in PBS, and seeded as described for the
Cells Postisolationfresh AEC prior to their use in PBL assays as detailed
above. The human islet isolation protocol employed in the
present study resulted in the harvest of structurally intactAEC-Conditioned Medium. In a separate set of ex-
islets, which were well cleaved from the surroundingperiments confluent monolayers of AEC were dispersed
exocrine tissue, as previously reported (26,27). The pu-and replated in T75 flasks in supplemented RPMI me-
rity of the islet suspension following Ficoll-assisted sep-dium as described above. The flasks were left for 72 h
aration ranged from 70% to 85%, with islets mostlywithout a medium change to allow concentration of pu-
sized between 100 and 500 µm. Trypan blue exclusiontative soluble factors released by the AEC. The resulting
served as an indicator of preserved islet structural integ-AEC-conditioned medium was harvested and centri-
rity.fuged at 1300 × g to ensure removal of all cells and cel-
AEC plated at high density in T75 flasks readilylular debris prior to use in PBL proliferation assays.
attached and flattened to form a monolayer (Fig. 1A);Conditioned medium (0.5 ml) was dispensed to the ap-
the vast majority of these cells stained positive for thepropriate wells of a 24-well plate and 5 × 104 resting
epithelial cell marker cytokeratin 19 (Fig. 1B). A dis-or PHA-activated PBLs were added, adjusting the total
creet subpopulation of cells also stained positive for thevolume to 1.0 ml using standard RPMI medium. Plates
intermediate filament marker vimentin (Fig. 1C) and awere incubated at 37°C, 5% CO2, 95% O2. After 72 h the
significant number (30%) expressed Fas ligand (Fig.PBLs were harvested and processed as described above.
1D). Islets held in coculture with AEC under CSC con-Results were expressed as a percentage of control (i.e.,
ditions demonstrated a degree of cell association: AECresting PBLs incubated in the absence of AEC-condi-
were overlying islets in some instances (Fig. 2) andtioned medium).
more robust, tightly formed cellular constructs exhibit-Islet/AEC Cocultures. As the islets and islet/AEC ing good integration of the two cell types were achieved
cultures maintained within the RCCS demonstrated su- by 72-h coculture of islets and AEC within the RCCSperior viability both with regard to morphology (islet/ (Fig. 3). The vast majority of islets within the RCCSAEC integration) and insulin secretory capacity com- became associated with AEC although, in most in-pared to those held under CSC conditions, these cultures
stances, the AEC did not form a complete layer.
were subjected to PBL proliferation studies. Cells were
transferred from the HARVs to 24-well plates (50–100 Islet Secretory Function at 24 h Postisolation
IEQ or 50–100 islet/AEC aggregates/well). Following a Islets maintained under CSC conditions for a period
48-h period to allow attachment the islet or islet/AEC
of 24 h postisolation demonstrated functional viability
cultures were exposed to either resting or PHA-activated
as indicated by their response to a glucose challenge.
PBLs (5 × 104 cell per well) for a period of 72 h, after Insulin secretion was consistently increased by 16.7 mM
which time the PBLs were harvested and analyzed for glucose (SI 2.63 ± 0.21) compared with basal release.
ATP content as described above. This was further enhanced by the presence of 10 mM
theophylline (SI 3.67 ± 0.34) (Fig. 4).Statistical Analysis
Impact of islet/AEC Coculture ConditionStatistical differences between the culture conditions
on β-Cell Functionin response to insulin secretagogues were assessed by
one-way analysis of variance (ANOVA) using islet mo- Following a 72-h period of culture islet and islet/
AEC constructs were subjected to further glucose chal-nocultures maintained under CSC conditions as the con-
trol group. Significant differences in PBL proliferation lenge studies. Preliminary experiments indicated that
isolated AEC do not secrete insulin when maintained inin response to AEC, conditioned medium, islets or islet/
AECs were determined using Mann-Whitney U and Tu- either static or rotational culture (data not shown) and
were therefore not assessed during this investigation. Inkey’s multiple comparison tests (by Rank), with the re-
sponse of resting PBLs serving as the control. In all the presence of elevated (16.7 mM) glucose, control is-
lets held under CSC conditions throughout the period ofcomparisons a value of p < 0.05 was considered to be
AMNION CELL-DERIVED IMMUNOSUPPRESSION 527
Figure 1. Morphological characteristics of human amniotic epithelial cells (AEC) in confluent monolayer culture. Phase contrast
visualization of isolated human AEC (A). Immunocytochemical localisation of cytokeratin 19 (CK-19) (B), vimentin (C), and Fas
Ligand (FasL) (D). Scale bar: 100 µm.
the investigation responded minimally in terms of insu- tively; SI 1.83 ± 0.11 and 3.15 ± 0.32 for islets main-
tained in the RCCS in response to 16.7 mM glucoselin secretion (SI 1.24 ± 0.07), as previously noted (26,
27), although a combination of 16.7 mM glucose and 10 alone and 16.7 mM glucose plus 10 mM theophylline,
respectively) (Fig. 5).mM theophylline elicited more marked (p < 0.05) insu-
lin secretion (SI 1.53 ± 0.1) (Fig. 5). By contrast, main-
PBL Proliferation: Influence of AECtenance of islets within the RCCS preserved glucose re-
and AEC-Conditioned Mediumsponsiveness with significant insulin secretion occurring
in response to 16.7 mM glucose both in the absence (SI PBLs taken from healthy volunteers demonstrated a
six- to ninefold stimulation in the presence of 5 µg/ml1.59 ± 0.08; p < 0.05) and the presence (SI 2.49 ± 0.28;
p < 0.01) of the potentiator. Coculture of islets with PHA for a period of 72 h (Fig. 6A, B). Resting PBLs
failed to respond on contact with an equal number ofAEC under both CSC conditions or within the RCCS
had an apparently beneficial effect on β-cell function, AEC or on exposure to AEC-conditioned medium over
the same time period. The proliferation of PHA-acti-with islets continuing to respond to glucose stimulation
(SI 1.65 ± 0.12 and 2.89 ± 0.34 for islets under CSC vated lymphocytes was abrogated by coculture with
AEC (Fig. 6A). A similar inhibition to PHA-mediatedcondition in response to 16.7 mM glucose alone and
16.7 mM glucose plus 10 mM theophylline, respec- PBL proliferation was seen in AEC subjected to a period
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Figure 2. Morphological characteristics of human islet/AEC constructs formed by coculture under conventional static culture (CSC)
conditions for 72 h. Phase contrast image of typical cell construct (A). Immunocytochemical localization of insulin (TRITC) (B)
and CK19 (FITC) (C). Overlay image showing the spatial interaction of the two cell types (D). Scale bar: 50 µm.
of cryopreservation. Furthermore, AEC-conditioned me- properties in vitro as indicated by their ability to sup-
press mitogen-induced lymphocyte proliferation, thusdium had comparable immunosuppressive activity on
PHA-activated PBLs (Fig. 6B). confirming previous studies (1,24,41). In addition, the
outcome of the coculture studies suggests, for the first
PBL Proliferation: Islets Versus Islet/AEC time, that the immunosuppressive properties of AEC
may confer a state of immune privilege in otherwise im-Exposure of resting PBL to unmodified human islets
that were maintained within the RCCS elicited a marked munogenic cells. These novel observations are relevant
to the potential use of human AEC as an adjunct to cell(p < 0.05) proliferative response (Fig. 7A). By contrast,
the presence of AEC attenuated resting PBL prolifera- replacement therapies, such as islet transplantation. Con-
ceivably, the creation of a localized region of immuno-tion. PHA-stimulated PBL proliferation was sustained
on contact with isolated islets, but was significantly (p < suppression might reduce or obviate the obligatory re-
quirement for chronic immunosuppressive therapy.0.01) suppressed when islets were in coculture with AEC
(Fig. 7B). Notwithstanding their disparate origins, the coculture
of human islets and AEC under either conventional
static or rotational cell culture conditions resulted in suc-DISCUSSION
cessful physical interaction between the two cell types.
As previously reported (27), the RCCS provided a moreThis investigation has demonstrated that human am-
niotic epithelial cells possess innate immunoregulatory conducive environment for cellular aggregation, with the
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formation of robust constructs exhibiting frequent spa- a beneficial impact of ductal epithelial cell coculture in
preserving islet function (26), apparently due to theirtial association of the insulin- and CK19-expressing
cells and a preserved islet-like morphology. The high ability to provide trophic support to neighboring β-cells
(29). AEC are also reported to synthesize and secrete aaspect ratio vessels (HARVs) are designed to create a
microgravity environment with low shear forces permit- range of growth factors that may have relevance for the
sustained functional viability of islets seen in the cocul-ting a greater degree of cell–cell interaction (38), which
may underlie the efficient formation of stable islet/AEC ture model. Of note, mRNA expression of TGF-β, EGF,
and KGF, known mediators of β-cell replication (7,12,constructs observed in the present study.
The close proximity of AEC to the human islets had 25) has been reported in intact human amniotic mem-
brane and isolated amniotic epithelial cells (21). Further-no adverse effect on β-cell function. Indeed, the insulin
secretion data indicate preservation of glucose sensitiv- more, dissociated AEC secrete biologically active neuro-
trophins including BDNF (18), which have been linkedity in human islets maintained in coculture with AEC.
This may be compared with islets held alone under CSC to β-cell development and survival (31). It is thus likely
that the close association of AEC to islets in this cocul-conditions, which showed a diminution of glucose re-
sponsiveness. In previous studies we have demonstrated ture model permits the paracrine release of soluble me-
Figure 3. Morphological characteristics of human islet/AEC constructs formed in rotational cell culture (RCCS) over 72 h. Phase
contrast image of typical cell construct (A). Immunocytochemical localisation of insulin (TRITC) (B) and CK19 (FITC) (C).
Overlay image showing the spatial interaction of the two cell types (D). Scale bar: 100 µm.
530 QURESHI ET AL.
Figure 4. Insulin secretion from isolated human islets in response to nutrient stimulation during
static challenge experiments performed 24 h postisolation. Islets were maintained under CSC con-
ditions prior to assessment of secretory function. Insulin release was measured in response to 1.67
mmol/L glucose (basal release), 16.7 mmol/L glucose, and 16.7 mmol/L glucose plus 10 mmol/L
theophylline. Results are expressed as the mean ± SEM fold increase in insulin release in response
to nutrient stimulation relative to release under basal conditions. n = 7 independent islet prepara-
tions. The absolute mean value for insulin secretion under basal conditions was 86.5 ± 17.2 µUml−1
[20 islets]−1 h−1. *p < 0.05 versus basal conditions.
diators able to support insulin secretory capacity in the on complete encapsulation of the islets by the AEC, fur-
ther indicative of a role for soluble immunoregulatorypostisolation period with beneficial consequences for
long-term β-cell function. factors. Also, the immunomodulatory response to acti-
vated (PHA-stimulated) T cells was as robust in the is-The immunomodulatory capabilities of human amni-
otic membrane have been studied extensively (15,22, let/AEC cocultures as in AEC monocultures. Combined,
these data suggest that AEC exhibit a potent and gener-36). Our findings that isolated AEC abrogate mitogen-
induced PBL proliferation confirm the results of pre- alized immunosuppressive capability, inducing an anti-
proliferative response in T cells subjected both to spe-viously published studies using comparable amnion-
derived epithelial cell populations (24,41). Hence, our cific and nonspecific antigen challenge.
Studies to identify the soluble factors involved inextrapolation that the immunosuppressive properties of
isolated AEC could be manipulated to confer a state of AEC-mediated immunosuppression and to characterize
their T-cell targets are ongoing, yet initial immunocyto-immune privilege on other cells capable of provoking
an immune response. The findings of the conditioned chemical evidence indicates the potential involvement of
Fas ligand (FasL), an immunomodulatory factor associ-medium studies support those of others (15,24,37), and
further suggest that AEC secrete immunomodulatory ated with naturally occurring T-cell evasion in the testis,
eye, and brain (10). Localization of FasL within the pla-factors at concentrations sufficient to create a region of
localized immunosuppression, with the potential to alter centa and amnio-chorionic membranes is implicated in
maternal tolerance developed to the fetus during preg-the immunogenicity of other cells in their immediate vi-
cinity. Thus, in our mixed islet/lymphocyte reaction sus- nancy (13,19). Thus, FasL in the AEC cultures raises
the possibility of activated, FasL-mediated T-cell apo-tained proliferation of resting PBL was demonstrated in
the presence of unmodified islets, yet those that were ptosis. It is unlikely that a single mediator is responsible
for immune adaptation and, indeed, other soluble factorsclosely associated (cocultured) with AEC failed to elicit
an allogeneic response. This effect was not dependent have been identified within the AEC population, includ-
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Figure 5. Glucose-stimulated insulin release from human islets (HI) maintained under conventional
static culture (CSC) conditions or within the rotational cell culture system (RCCS) either in the
presence or absence of human amniotic epithelial cells (AEC) for 72 h. Insulin release was mea-
sured in response to 1.67 mmol/L glucose (open bars), 16.7 mmol/L glucose (gray bars), and 16.7
mmol/L glucose plus 10 mmol/L theophylline (filled bars). Results are expressed as the ratio of
stimulated insulin release compared to basal, mean ± SEM. n = 4. *p < 0.05, **p < 0.01 stimulated
insulin secretion compared to basal release.
Figure 6. Modulation of peripheral blood lymphocyte (PBL) proliferation by (A) the presence of human amniotic epithelial cells
(AEC), and (B) exposure to AEC-conditioned medium (CM). Resting (r; open bars) or PHA-activated (s, filled bars) human PBLs
were maintained in 24-well plates either alone, in the presence of an equal number of human amniotic epithelial cells, or 0.5 ml of
AEC-conditioned medium for a period of 72 h. The rate of PBL proliferation following this period was measured using an ATP
chemiluminescence assay. Data show the percentage increase above control (resting PBLs) from six individual AEC preps and
represents the typical observation in fresh and cryopreserved AEC. *p < 0.05, **p < 0.01 compared to control. †p < 0.01 for PHA-
activated PBL proliferation in the presence or absence of AEC/AEC-conditioned medium.
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Figure 7. Modulation of peripheral blood lymphocyte (PBL) proliferation by exposure to human islets and human islet/AEC
constructs. Resting (A) or PHA-activated (B) human PBLs were maintained in 24-well plates either alone or in the presence of
human islets (HI) or islet/AEC constructs for a period of 72 h. The rate of PBL proliferation following this period was measured
using an ATP chemiluminescence assay. Data depict the response from four individual human islet and AEC preps and represents
the typical observation. *p < 0.01 compared to resting levels. †p < 0.01 for PHA-activated PBL proliferation in the presence or
absence of human islet/AEC constructs.
ing TGF-β, HLA-G, and IL-10 (23,24), all of which ment of human AEC without evidence of tumorigenesis
has been reported (2). Future work will seek to demon-have the potential to affect localized immunosuppres-
sion. A number of these mediators could potentially op- strate that the immune-evasive properties of islet/AEC
constructs are sustained in vivo and define how such aerate in concert to produce a microenvironment capable
of sustaining allogeneic tissue by diminution of the T- bioengineered approach to immune suppression could be
adapted for clinical use.cell response.
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